hypertension - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

RGD DISEASE ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

RGD uses the Human Disease Ontology (DO, https://disease-ontology.org/) for disease curation across species. RGD automatically downloads each new release of the ontology on a monthly basis. Some additional terms which are required for RGD's curation purposes but are not currently covered in the official version of DO have been added. As corresponding terms are added to DO, these custom terms are retired and the DO terms substituted in existing annotations and subsequently used for curation.

Term:	hypertension	go back to main search page
Accession:	DOID:10763	browse the term
Definition:	An artery disease characterized by chronic elevated blood pressure in the arteries. (DO)
Synonyms:	exact_synonym:	HTN; high blood pressure; high blood pressures; hyperpiesia; vascular hypertensive disorder
	related_synonym:	hypertensive disease; increased aldosterone to renin ratio
	primary_id:	MESH:D006973
	xref:	EFO:0000537; ICD9CM:401-405.99; NCI:C3117
For additional species annotation, visit the Alliance of Genome Resources.

show annotations for term's descendants Sort by:
Rat (1628) Mouse (957) Human (4498) Chinchilla (843) Bonobo (904) Dog (923) Squirrel (856) Pig (914) Green Monkey (888) Naked Mole-rat (848) All
Genes (957)

hypertension

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

4-aminobutyrate aminotransferase

RGD

NCBI chr16:8,331,293...8,439,432
Ensembl chr16:8,331,293...8,439,432

G

ATP-binding cassette, sub-family C member 1

CTD Direct Evidence: marker/mechanism

NCBI chr16:14,179,317...14,292,743
Ensembl chr16:14,179,422...14,293,601

G

ATP-binding cassette, sub-family C member 8

associated with obesity;DNA:polymorphism:exon:

RGD

NCBI chr 7:45,753,952...45,829,441
Ensembl chr 7:45,753,947...45,829,457

G

ATP-binding cassette, sub-family C member 9

protein:decreased expression:aorta

RGD

PMID:15964031 PMID:18471810

RGD:1598644, RGD:2301909

NCBI chr 6:142,533,592...142,648,472
Ensembl chr 6:142,533,588...142,648,041

G

ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase

susceptibility

associated with COVID-19; DNA:polymorphism:cds:allele A (human)

RGD

NCBI chr 2:26,732,508...26,754,973
Ensembl chr 2:26,732,515...26,754,991

G

angiotensin I converting enzyme

treatment
susceptibility

CTD Direct Evidence: marker/mechanism
protein:increased activity:lung (rat)
DNA:polymorphism

CTD
RGD

PMID:15773232 PMID:17473847 PMID:20237592 PMID:27847271 PMID:17392119 More...

RGD:1601113, RGD:401793709, RGD:40400899, RGD:1581743, RGD:11039415, RGD:1331525, RGD:8157611, RGD:1601114

NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790

G

angiotensin converting enzyme 2

treatment

associated with Metabolic Syndrome X (MeSH:D024821)
mRNA, protein:decreased expression:kidney (rat)
CTD Direct Evidence: marker/mechanism|therapeutic
mRNA, protein:decreased expression:aorta

CTD
RGD

PMID:12075344 PMID:15833808 PMID:17473847 PMID:18391097 PMID:19221212 More...

RGD:1642828, RGD:629626, RGD:9685442, RGD:9685435, RGD:9685433

NCBI chr X:162,922,338...162,971,414
Ensembl chr X:162,922,328...162,971,416

G

acyl-CoA synthetase medium-chain family member 3

RGD

PMID:8507454 PMID:8094726

RGD:634023, RGD:61050

NCBI chr 7:119,360,106...119,384,119
Ensembl chr 7:119,360,146...119,386,736

G

actin, alpha, cardiac muscle 1

RGD

NCBI chr 2:113,877,763...113,883,356
Ensembl chr 2:113,877,763...113,884,029

G

adenosine deaminase

RGD

NCBI chr 2:163,565,703...163,592,154
Ensembl chr 2:163,568,504...163,592,159

G

ADAM metallopeptidase with thrombospondin type 1 motif 16

RGD

NCBI chr13:70,875,917...70,989,956
Ensembl chr13:70,875,921...70,989,930

G

adenylate cyclase 5

CTD Direct Evidence: marker/mechanism
mRNA:decreased expression:heart left ventricle

CTD
RGD

PMID:12717102 PMID:12717102

NCBI chr16:34,974,933...35,126,108
Ensembl chr16:34,975,247...35,126,108

G

adducin 1

DNA:polymorphism: :p.G460W (human)
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:15773232 PMID:19199261 PMID:9149697 PMID:15474463

RGD:1624953, RGD:1302895

NCBI chr 5:34,731,008...34,789,652
Ensembl chr 5:34,731,008...34,789,652

G

adducin 2

no_association

DNA:polymorphism
DNA:SNP: :rs4852706 (human)

RGD
GAD

PMID:16497648 PMID:24652215 PMID:15118671

RGD:1625293, RGD:10047131, RGD:1331525

NCBI chr 6:86,005,663...86,101,391
Ensembl chr 6:86,005,663...86,101,391

G

adducin 3

NCBI chr19:53,128,874...53,235,518
Ensembl chr19:53,128,874...53,235,830

G

adiponectin, C1Q and collagen domain containing

CTD Direct Evidence: marker/mechanism

NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778

G

adrenomedullin

mRNA, protein:increased expression:myocardium, aorta
protein:increased expression:plasma

RGD

PMID:16450076 PMID:16625237

RGD:1625300, RGD:1625298

NCBI chr 7:110,226,864...110,229,027
Ensembl chr 7:110,226,868...110,229,027

G

adenosine A1 receptor

treatment
no_association

associated with diabetes mellitus, experimental

RGD

PMID:8998253 PMID:9597368 PMID:15257174

RGD:1625366, RGD:1625365, RGD:1625367

NCBI chr 1:134,126,953...134,163,195
Ensembl chr 1:134,126,963...134,163,169

G

adenosine A2a receptor

no_association

RGD
GAD

PMID:15257174 PMID:15118671

RGD:1625367, RGD:1331525

NCBI chr10:75,152,711...75,170,626
Ensembl chr10:75,152,711...75,170,618

G

adrenergic receptor, alpha 1a

mRNA:decreased expression:aorta

RGD

PMID:16371063 PMID:19011682

RGD:1625770, RGD:5688340

NCBI chr14:66,872,705...67,009,549
Ensembl chr14:66,872,700...67,008,617

G

adrenergic receptor, alpha 1b

RGD

NCBI chr11:43,665,432...43,792,076
Ensembl chr11:43,665,433...43,792,037

G

adrenergic receptor, alpha 2a

no_association

DNA:polymorphism
CTD Direct Evidence: marker/mechanism
mRNA:decreased expression:adrenal gland medulla

CTD
RGD

PMID:10694191 PMID:16636200 PMID:20691504

RGD:1625183, RGD:6480490

NCBI chr19:54,033,690...54,037,413
Ensembl chr19:54,032,582...54,037,413

G

adrenergic receptor, alpha 2b

DNA:polymorphism (human)

RGD

PMID:17070424 PMID:18953403

RGD:2313548, RGD:2313541

NCBI chr 2:127,205,099...127,209,141
Ensembl chr 2:127,205,128...127,209,141

G

adrenergic receptor, beta 1

protein:increased expression:aorta
CTD Direct Evidence: marker/mechanism
associated with Diabetes Mellitus, Type 2;

CTD
RGD

PMID:9260993 PMID:10673262 PMID:19060223 PMID:20398560

RGD:5129127, RGD:7241549

NCBI chr19:56,710,549...56,713,582
Ensembl chr19:56,710,631...56,721,545

G

adrenergic receptor, beta 2

no_association
susceptibility

DNA:polymorphisms: :p.R16G, p.Q27E
DNA:polymorphisms: :pG16R, p.Q27E, p.T164I (human)
associated with Kidney Failure, Chronic; DNA:SNP:cds:p.R16G (human)
DNA:polymorphisms: :46A>G, 79C>G (human)

RGD
GAD

PMID:17221209 PMID:16041242 PMID:15118671 PMID:2471888 PMID:20484896 More...

RGD:1601119, RGD:1578728, RGD:1331525, RGD:7175287, RGD:7175066, RGD:4144883, RGD:1601123

NCBI chr18:62,310,784...62,313,052
Ensembl chr18:62,310,887...62,313,030

G

adrenergic receptor, beta 3

associated with Diabetes Mellitus, Non-Insulin-Dependent;DNA:polymorphism: :p.W64R (human)

RGD

NCBI chr 8:27,715,804...27,720,833
Ensembl chr 8:27,715,804...27,740,644

G

advanced glycosylation end product-specific receptor

protein:increased expression:kidney
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:32147540 PMID:19018797

NCBI chr17:34,816,545...34,819,911
Ensembl chr17:34,816,836...34,819,910

G

angiotensinogen

treatment
no_association
susceptibility

ClinVar Annotator: match by term: Hypertension
CTD Direct Evidence: marker/mechanism|therapeutic
DNA:polymorphisms: :p.T174M, p.M235T (human)
DNA:polymorphisms: :-6G>A, p.M235T, p.T174M
DNA:polymorphism: :p.M235T
DNA:polymorphism:promoter:-20C>A (human)
protein:increased expression:plasma, urine
DNA:polymorphism: :p.M268T (human)

ClinVar
CTD
RGD

PMID:43064 PMID:1394429 PMID:1432030 PMID:1849535 PMID:1860718 More...

RGD:1358275, RGD:329956421, RGD:11039415, RGD:8549470, RGD:8549469, RGD:8549458, RGD:8548902, RGD:1300393, RGD:1331525, RGD:1601143, RGD:1601130, RGD:1601141, RGD:1601139, RGD:5129176, RGD:5129166

NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445

G

angiotensin II receptor, type 1a

treatment
no_association
susceptibility

CTD Direct Evidence: marker/mechanism
mRNA:increased expression:aortic endothelial cell
DNA:polymorphism:3' utr:1166A>C
DNA:polymorphism:3' utr:g.1166A>C
associated with Sleep Apnea Syndromes

CTD
RGD

PMID:8952600 PMID:19047579 PMID:23603059 PMID:27292124 PMID:21346625 More...

RGD:5129176, RGD:401793709, RGD:8549458, RGD:1331525, RGD:5147456, RGD:1601152, RGD:1601148, RGD:5129169

NCBI chr13:30,520,339...30,566,850
Ensembl chr13:30,520,424...30,566,850

G

angiotensin II receptor, type 1b

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:22728133 PMID:27847271 PMID:10994756

NCBI chr 3:20,368,637...20,421,341
Ensembl chr 3:20,368,637...20,421,341

G

angiotensin II receptor, type 2

associated with Sleep Apnea Syndromes
CTD Direct Evidence: marker/mechanism
mRNA, protein:decreased expression:kidney

CTD
RGD

PMID:15710752 PMID:21040717 PMID:11924718 PMID:19680135

RGD:5129169, RGD:6903865, RGD:6903372

NCBI chr X:21,350,863...21,355,072
Ensembl chr X:21,350,783...21,355,403

G

angiotensin II, type I receptor-associated protein

protein:increased expression:kidney

RGD

NCBI chr 4:148,161,518...148,172,521
Ensembl chr 4:148,161,518...148,172,488

G

alanine-glyoxylate aminotransferase 2

DNA:SNP, haplotype:exon:multiple (human)

RGD

NCBI chr15:10,358,602...10,410,244
Ensembl chr15:10,358,618...10,410,239

G

S-adenosylhomocysteine hydrolase

associated with hyperhomocysteinemia

RGD

NCBI chr 2:154,901,230...154,916,417
Ensembl chr 2:154,901,230...154,916,417

G

aryl-hydrocarbon receptor

treatment

CTD Direct Evidence: marker/mechanism
associated with chronic intermittent hypoxia

CTD
RGD

PMID:21115475 PMID:31489946 PMID:23528973 PMID:32416216 PMID:30127255

RGD:401793758, RGD:401793732, RGD:401793731, RGD:401793709

NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037

G

aryl-hydrocarbon receptor repressor

treatment

RGD

PMID:30127255 PMID:31489946

RGD:401793709, RGD:401793758

NCBI chr13:74,359,237...74,440,450
Ensembl chr13:74,359,237...74,440,450

G

allograft inflammatory factor 1

CTD Direct Evidence: marker/mechanism

NCBI chr17:35,389,967...35,394,977
Ensembl chr17:35,389,967...35,395,044

G

thymoma viral proto-oncogene 1

protein:increased serine phosphorylation:kidney

RGD

NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318

G

thymoma viral proto-oncogene 2

mRNA:increased expression:cerebral cortex (rat)

RGD

NCBI chr 7:27,290,977...27,340,251
Ensembl chr 7:27,290,977...27,340,251

G

aminolevulinate, delta-, dehydratase

no_association

DNA:polymorphism
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:20123609 PMID:11335187

NCBI chr 4:62,422,762...62,438,300
Ensembl chr 4:62,427,406...62,438,155

G

albumin

CTD Direct Evidence: therapeutic

NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461

G

aldehyde dehydrogenase 2, mitochondrial

susceptibility
no_association

RGD

PMID:11510748 PMID:12484509

RGD:1601164, RGD:1601163

NCBI chr 5:121,704,090...121,731,887
Ensembl chr 5:121,704,090...121,731,887

G

arachidonate 12-lipoxygenase

mRNA:decreased expression:medulla oblongata

RGD

NCBI chr11:70,132,283...70,146,206
Ensembl chr11:70,132,283...70,146,179

G

arachidonate 15-lipoxygenase

CTD Direct Evidence: marker/mechanism

NCBI chr11:70,234,973...70,279,465
Ensembl chr11:70,234,978...70,242,857

G

arachidonate 5-lipoxygenase

RGD

NCBI chr 6:116,387,030...116,438,139
Ensembl chr 6:116,387,038...116,438,139

G

angiopoietin 1

protein:increased expression:plasma, platelet

RGD

PMID:16942942 PMID:18285514

RGD:1626157, RGD:2316068

NCBI chr15:42,288,063...42,540,373
Ensembl chr15:42,288,119...42,540,373

G

angiopoietin 2

RGD

NCBI chr 8:18,740,279...18,791,578
Ensembl chr 8:18,740,279...18,791,578

G

annexin A1

protein:altered localization:vascular associated smooth muscle cell
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:22228705 PMID:16109804

NCBI chr19:20,350,798...20,368,035
Ensembl chr19:20,350,792...20,368,308

G

amine oxidase, copper-containing 1

CTD Direct Evidence: marker/mechanism

NCBI chr 6:48,872,189...48,886,122
Ensembl chr 6:48,849,830...48,886,122

G

amine oxidase, copper containing 3

CTD Direct Evidence: marker/mechanism

NCBI chr11:101,221,432...101,230,256
Ensembl chr11:101,221,431...101,232,764

G

apelin

mRNA:decreased expression:aorta, heart

RGD

NCBI chr X:47,114,023...47,123,730
Ensembl chr X:47,114,023...47,123,730

G

apolipoprotein A-I

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:18224302 PMID:23401751

NCBI chr 9:46,139,928...46,141,767
Ensembl chr 9:46,139,878...46,141,764

G

apolipoprotein B

GAD

NCBI chr12:8,027,629...8,066,839
Ensembl chr12:8,027,648...8,066,835

G

apolipoprotein E

onset

mRNA:decreased expression:multiple (rat)
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:20720404 PMID:22228705 PMID:20585107 PMID:15118671

RGD:6904214, RGD:1331525

NCBI chr 7:19,430,169...19,434,326
Ensembl chr 7:19,430,034...19,433,113

G

amyloid beta precursor protein

RGD

NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654

G

aquaporin 1

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:22228705 PMID:20156423

NCBI chr 6:55,313,284...55,325,540
Ensembl chr 6:55,313,417...55,325,540

G

aquaporin 2

protein:increased expression:kidney medulla

RGD

NCBI chr15:99,476,937...99,482,426
Ensembl chr15:99,476,936...99,482,428

G

aquaporin 4

RGD

NCBI chr18:15,522,451...15,544,039
Ensembl chr18:15,522,553...15,544,039

G

androgen receptor

treatment

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:10523385 PMID:15746697 PMID:12397037

RGD:1601245, RGD:10043316

NCBI chr X:97,192,363...97,366,824
Ensembl chr X:97,192,375...97,366,821

G

arginase, liver

mRNA:increased expression:aorta (rat)

RGD

PMID:18475148 PMID:17223136

RGD:4142834, RGD:1626296

NCBI chr10:24,791,105...24,803,368
Ensembl chr10:24,791,119...24,803,382

G

arginase type II

mRNA:increased expression:lung
mRNA:increased expression:aorta (rat)

RGD

PMID:20039818 PMID:17223136 PMID:18475148

RGD:4143278, RGD:1626296, RGD:4142834

NCBI chr12:79,177,562...79,203,075
Ensembl chr12:79,177,551...79,203,075

G

Rho GDP dissociation inhibitor alpha

mRNA:decreased expression:urinary bladder
protein:decreased expression:cortical collecting duct

RGD

PMID:19689474 PMID:25164814

RGD:9684972, RGD:9684979

NCBI chr11:120,468,925...120,472,450
Ensembl chr11:120,468,930...120,472,450

G

AT-rich interaction domain 1B

treatment

RGD

NCBI chr17:5,044,481...5,397,931
Ensembl chr17:5,044,607...5,397,931

G

aryl hydrocarbon receptor nuclear translocator

treatment

RGD

PMID:23528973 PMID:31489946

RGD:401793732, RGD:401793758

NCBI chr 3:95,341,674...95,404,551
Ensembl chr 3:95,341,699...95,404,551

G

arrestin, beta 2

protein:decreased expression:rostral ventrolateral medulla

RGD

NCBI chr11:70,323,051...70,331,654
Ensembl chr11:70,323,461...70,331,654

G

activating transcription factor 2

RGD

NCBI chr 2:73,646,853...73,723,094
Ensembl chr 2:73,646,853...73,722,983

G

autophagy related 7

protein:increased expression:skeletal muscle

RGD

NCBI chr 6:114,620,075...114,837,565
Ensembl chr 6:114,620,058...114,837,575

G

antioxidant 1 copper chaperone

CTD Direct Evidence: therapeutic

NCBI chr11:55,337,463...55,352,034
Ensembl chr11:55,337,467...55,352,065

G

ATPase, Na+/K+ transporting, alpha 1 polypeptide

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:23416519 PMID:8082931

NCBI chr 3:101,483,535...101,512,023
Ensembl chr 3:101,483,535...101,512,000

G

ATPase, Na+/K+ transporting, alpha 2 polypeptide

susceptibility

protein:decreased expression:adrenal gland cortex zone
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:16166162 PMID:16243970 PMID:11768735 PMID:16243970 PMID:11257061

RGD:1601253, RGD:1601251, RGD:1601254

NCBI chr 1:172,099,276...172,125,631
Ensembl chr 1:172,099,276...172,125,631

G

ATPase, Ca++ transporting, ubiquitous

RGD

NCBI chr11:72,851,995...72,883,869
Ensembl chr11:72,851,995...72,883,870

G

ATPase, Ca++ transporting, plasma membrane 1

mRNA:increased expression:vascular associated smooth muscle cell
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:19430479 PMID:20137670

NCBI chr10:98,750,243...98,862,005
Ensembl chr10:98,750,268...98,862,005

G

ATPase, Ca++ transporting, plasma membrane 3

CTD Direct Evidence: marker/mechanism

NCBI chr X:72,546,356...72,632,267
Ensembl chr X:72,546,692...72,614,611

G

ATP synthase F1 subunit alpha

protein:decreased expression:heart left ventricle (rat)

RGD

NCBI chr18:77,861,468...77,870,569
Ensembl chr18:77,861,429...77,870,569

G

ATPase, H+ transporting, lysosomal accessory protein 2

RGD

NCBI chr X:12,453,998...12,483,290
Ensembl chr X:12,454,040...12,483,288

G

arginine vasopressin

protein:increased expression:carotid artery
CTD Direct Evidence: marker/mechanism
protein:increased expression:plasma

CTD
RGD

PMID:1663982 PMID:3346065 PMID:4040330 PMID:6367368 PMID:19133994 More...

RGD:1601305, RGD:1601243

NCBI chr 2:130,422,540...130,424,508
Ensembl chr 2:130,422,540...130,424,474

G

arginine vasopressin receptor 1A

mRNA, protein:increased expression:kidney, arteriole
mRNA, protein:increased expression:paraventricular hypothalamic nucleus
DNA:SNP

RGD

PMID:15657301 PMID:15475662 PMID:17653244

RGD:2300322, RGD:2300330, RGD:2300319

NCBI chr10:122,284,404...122,289,358
Ensembl chr10:122,284,404...122,289,357

G

arginine vasopressin receptor 2

severity

RGD

NCBI chr X:72,935,371...72,938,034
Ensembl chr X:72,935,708...72,939,108

G

beta-2 microglobulin

protein:increased expression:serum

RGD

NCBI chr 2:121,978,168...121,983,563
Ensembl chr 2:121,978,167...121,983,564

G

BCL2-associated agonist of cell death

treatment

RGD

NCBI chr19:6,919,229...6,929,273
Ensembl chr19:6,919,229...6,929,267

G

BCL2-associated X protein

treatment

RGD

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

butyrylcholinesterase

RGD

NCBI chr 3:73,543,138...73,615,767
Ensembl chr 3:73,543,141...73,615,748

G

B cell leukemia/lymphoma 2

treatment

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:10075388 PMID:20065158

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

bradykinin receptor, beta 1

RGD

PMID:17988733 PMID:12025958 PMID:15643125

RGD:5129214, RGD:704378, RGD:1625732

NCBI chr12:105,570,350...105,571,770
Ensembl chr12:105,569,344...105,571,687

G

bradykinin receptor, beta 2

DNA:SNP:promoter:-58T>C (human)
CTD Direct Evidence: marker/mechanism
protein:increased expression:spinal cord
mRNA:increased expression:hypothalamus

CTD
RGD

PMID:10614985 PMID:10904024 PMID:11934804 PMID:15118671 PMID:12025958

RGD:4891034, RGD:4890455, RGD:1331525, RGD:704378

NCBI chr12:105,529,431...105,561,503
Ensembl chr12:105,529,485...105,561,496

G

beclin 1, autophagy related

protein:increased expression:brain

RGD

NCBI chr11:101,179,084...101,193,112
Ensembl chr11:101,176,778...101,193,112

G

basic helix-loop-helix ARNT like 2

DNA:SNPs: :rs6486121, rs3789327, rs969485(human)

RGD

NCBI chr 6:146,696,230...146,735,027
Ensembl chr 6:146,697,553...146,735,027

G

bone morphogenetic protein 2

treatment

RGD

NCBI chr 2:133,394,079...133,404,816
Ensembl chr 2:133,394,079...133,404,805

G

breast cancer 1, early onset

treatment

RGD

NCBI chr11:101,379,587...101,442,808
Ensembl chr11:101,379,590...101,442,781

G

bombesin-like receptor 3

RGD

NCBI chr X:56,088,434...56,094,118
Ensembl chr X:56,088,434...56,094,118

G

complement component 3

RGD

NCBI chr17:57,510,967...57,535,136
Ensembl chr17:57,510,970...57,535,136

G

calcium channel, voltage-dependent, L type, alpha 1C subunit

CTD Direct Evidence: marker/mechanism

NCBI chr 6:118,564,201...119,174,345
Ensembl chr 6:118,564,201...119,173,851

G

calcium channel, voltage-dependent, alpha2/delta subunit 1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:16,139,390...16,579,509
Ensembl chr 5:16,139,786...16,579,502

G

calcium channel, voltage-dependent, beta 2 subunit

susceptibility

DNA:SNP: :rs4373814(human)

RGD

NCBI chr 2:14,608,672...14,993,622
Ensembl chr 2:14,607,899...14,992,719

G

calcitonin/calcitonin-related polypeptide, alpha

CTD Direct Evidence: therapeutic

PMID:1849535 PMID:9887042

NCBI chr 7:114,225,223...114,236,145
Ensembl chr 7:114,230,713...114,235,592

G

calpain 6

associated with high salt diet; mRNA:decreased expression:heart (rat)

RGD

NCBI chr X:142,585,232...142,610,408
Ensembl chr X:142,585,227...142,610,410

G

calpain 9

associated with high salt diet; mRNA:decreased expression:heart (rat)

RGD

NCBI chr 8:125,301,361...125,345,470
Ensembl chr 8:125,302,850...125,345,470

G

caspase 3

treatment

RGD

PMID:20065158 PMID:27929425

RGD:10053702, RGD:13782308

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

caspase 8

RGD

NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662

G

caspase 9

RGD

NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287

G

calpastatin

associated with high salt diet; mRNA:increased expression:heart (rat)

RGD

NCBI chr13:74,840,485...74,956,993
Ensembl chr13:74,840,487...74,956,929

G

catalase

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:11479740 PMID:20667508 PMID:21593737 PMID:22228705 PMID:16716903

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

caveolin 1, caveolae protein

protein:increased expression:artery smooth muscle, blood vessel endothelial cell
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:1798635 PMID:17986358

NCBI chr 6:17,306,387...17,341,323
Ensembl chr 6:17,306,334...17,341,451

G

cystathionine beta-synthase

CTD Direct Evidence: marker/mechanism

NCBI chr17:31,831,602...31,856,170
Ensembl chr17:31,827,868...31,856,212

G

C-C motif chemokine ligand 2

ameliorates
treatment

protein:increased expression:urine
associated with Cardiac Fibrosis
CTD Direct Evidence: marker/mechanism
associated with Diabetes Mellitus, Non-Insulin-Dependent;mRNA, protein:increased expression:kidney cortex, urine

CTD
RGD

PMID:20667508 PMID:27292124 PMID:17989143 PMID:25715999 PMID:17922026 More...

RGD:2307054, RGD:401794570, RGD:8549771, RGD:2307029

NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279

G

C-C motif chemokine ligand 28

no_association

protein:increased expression:kidney (rat)
mRNA, protein:decreased expression:kidney (rat)

RGD

PMID:16840655 PMID:19829664

RGD:2298761, RGD:4892132

NCBI chr13:120,085,355...120,115,895
Ensembl chr13:120,085,355...120,115,895

G

C-C motif chemokine ligand 5

associated with Diabetes Mellitus, Non-Insulin-Dependent;protein:increased expression:serum

RGD

NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344

G

cellular communication network factor 2

CTD Direct Evidence: marker/mechanism

NCBI chr10:24,471,340...24,474,581
Ensembl chr10:24,471,340...24,474,581

G

cyclin E1

protein:increased expression:vascular associated smooth muscle cell

RGD

NCBI chr 7:37,797,409...37,806,915
Ensembl chr 7:37,797,409...37,806,959

G

C-C motif chemokine receptor 5

mRNA:increased expression:aorta (rat)
DNA:frameshift mutation:cds:p.S185_T195del rs333 (human)

RGD

PMID:20044442 PMID:12680626

RGD:4890416, RGD:1581182

NCBI chr 9:123,921,557...123,934,153
Ensembl chr 9:123,921,580...123,947,736

G

CD14 antigen

associated with Glomerulonephritis, IGA; DNA:polymorphism: :-159C>T (human)

RGD

NCBI chr18:36,858,117...36,859,868
Ensembl chr18:36,858,120...36,859,851

G

CD36 molecule

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:18587397 PMID:18587397

NCBI chr 5:17,986,680...18,093,828
Ensembl chr 5:17,986,688...18,093,799

G

CD82 antigen

mRNA:increased expression:thymus

RGD

NCBI chr 2:93,249,447...93,293,295
Ensembl chr 2:93,249,456...93,293,485

G

cyclin dependent kinase inhibitor 2A

protein:increased expression:kidney

RGD

NCBI chr 4:89,192,710...89,212,856
Ensembl chr 4:89,192,708...89,212,890

G

cysteine dioxygenase 1, cytosolic

protein:decreased expression:brain

RGD

NCBI chr18:46,846,260...46,861,569
Ensembl chr18:46,846,260...46,861,462

G

chymotrypsin-like elastase family, member 2A

CTD Direct Evidence: marker/mechanism
ClinVar Annotator: match by term: Hypertension

PMID:21602471 PMID:25741868 PMID:31358993

NCBI chr 4:141,542,265...141,553,316
Ensembl chr 4:141,542,273...141,553,471

G

chromogranin A

no_association

protein:creased expression:adrenal gland
mRNA, protein:increased expression:adrenal gland medulla, plasma
DNA:polymorphisms:promoter

RGD

PMID:21061160 PMID:10803489 PMID:10803489 PMID:20113265 PMID:20729505

RGD:6906897, RGD:6907055, RGD:6907055, RGD:6906902, RGD:6906900

NCBI chr12:102,521,200...102,531,286
Ensembl chr12:102,521,228...102,531,287

G

chitinase 3 like 1

mRNA:increased expression:brainstem, solitary tract nucleus (rat)

RGD

NCBI chr 1:134,109,894...134,117,769
Ensembl chr 1:134,109,914...134,117,919

G

carbohydrate sulfotransferase 12

mRNA:decreased expression:renal cortex and medulla (rat)

RGD

NCBI chr 5:140,491,398...140,510,993
Ensembl chr 5:140,491,305...140,511,479

G

chloride channel, voltage-sensitive Ka

CTD Direct Evidence: marker/mechanism

NCBI chr 4:141,111,922...141,126,017
Ensembl chr 4:141,111,921...141,126,035

G

chloride channel, voltage-sensitive Kb

no_association

DNA:polymorphism:T481S

RGD

PMID:15148291 PMID:16003175

RGD:1600684, RGD:1600683

NCBI chr 4:141,131,668...141,143,440
Ensembl chr 4:141,131,664...141,143,325

G

claudin 16

Protein:decreased serine phosphorylation:kidney

RGD

NCBI chr16:26,281,885...26,301,515
Ensembl chr16:26,281,885...26,301,515

G

clock circadian regulator

mRNA:altered expression:gastrocnemius muscle (rat)

RGD

NCBI chr 5:76,357,715...76,452,675
Ensembl chr 5:76,357,715...76,452,639

G

clusterin

DNA:SNP:exon:866C>T (human)

RGD

NCBI chr14:66,206,093...66,218,992
Ensembl chr14:66,205,932...66,218,996

G

chymase 1, mast cell

CTD Direct Evidence: marker/mechanism

NCBI chr14:56,178,908...56,182,132
Ensembl chr14:56,178,908...56,182,132

G

cannabinoid receptor 1

RGD

NCBI chr 4:33,923,171...33,948,831
Ensembl chr 4:33,924,593...33,948,831

G

collagen, type I, alpha 1

CTD Direct Evidence: marker/mechanism

NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868

G

collagen, type III, alpha 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:45,350,698...45,388,866
Ensembl chr 1:45,350,698...45,388,866

G

collagen, type IV, alpha 5

ClinVar Annotator: match by term: Hypertension

PMID:9848783 PMID:11223851 PMID:12028435 PMID:17396119 PMID:19728970 More...

NCBI chr X:140,258,367...140,472,232
Ensembl chr X:140,258,381...140,472,230

G

collagen, type VI, alpha 3

DNA:SNP:CDS:E1386K (rs146092501) (human)

RGD

NCBI chr 1:90,694,582...90,771,710
Ensembl chr 1:90,693,645...90,771,693

G

catechol-O-methyltransferase

susceptibility

DNA:polymorphism: :-1187G>C, 186C>T
protein:increased expression:cerebral cortex

RGD

PMID:14714585 PMID:17510509 PMID:17143180 PMID:17978496

RGD:2289787, RGD:8662344, RGD:2289742, RGD:2289729

NCBI chr16:18,225,632...18,247,006
Ensembl chr16:18,225,636...18,245,602

G

corin, serine peptidase

RGD

PMID:17485366 PMID:16216958

RGD:1626338, RGD:1581219

NCBI chr 5:72,457,291...72,661,884
Ensembl chr 5:72,457,368...72,661,816

G

cytochrome c oxidase subunit 5B

protein:decreased expression:heart left ventricle

RGD

NCBI chr 1:36,730,568...36,732,469
Ensembl chr 1:36,730,530...36,732,762

G

carbamoyl-phosphate synthetase 1

protein:decreased expression:liver, mitochondrion

RGD

NCBI chr 1:67,151,294...67,270,426
Ensembl chr 1:67,162,185...67,270,418

G

cAMP responsive element binding protein 1

treatment

RGD

NCBI chr 1:64,571,963...64,643,707
Ensembl chr 1:64,571,804...64,643,707

G

corticotropin releasing hormone receptor 1

corticotropin releasing hormone-induced

RGD

NCBI chr11:104,021,289...104,066,349
Ensembl chr11:104,023,681...104,066,349

G

corticotropin releasing hormone receptor 2

CTD Direct Evidence: marker/mechanism

NCBI chr 6:55,067,033...55,110,001
Ensembl chr 6:55,067,034...55,110,001

G

C-reactive protein, pentraxin-related

protein:increased expression:plasma
CTD Direct Evidence: marker/mechanism
protein:increased expression:serum:

CTD
RGD

PMID:14620923 PMID:16680063 PMID:19770776 PMID:20667508 PMID:19905982 More...

RGD:5131461, RGD:9586008, RGD:9491754

NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598

G

cardiotrophin 1

protein:increased expression:plasma
mRNA:increased expression:cardiac ventricle

RGD

PMID:15716706 PMID:8604995

RGD:1626411, RGD:69823

NCBI chr 7:127,311,872...127,317,360
Ensembl chr 7:127,311,908...127,317,364

G

cathepsin C

RGD

NCBI chr 7:87,927,233...87,960,083
Ensembl chr 7:87,927,293...87,960,096

G

C-X-C motif chemokine ligand 2

CTD Direct Evidence: marker/mechanism

NCBI chr 5:91,051,758...91,053,797
Ensembl chr 5:91,051,730...91,053,797

G

C-X-C motif chemokine receptor 2

CTD Direct Evidence: marker/mechanism

NCBI chr 1:74,193,153...74,200,405
Ensembl chr 1:74,193,150...74,200,405

G

cytochrome b-245, alpha polypeptide

protein:increased expression:kidney cortex
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:16685210 PMID:17324946 PMID:20505675 PMID:32147540 PMID:20018820 More...

RGD:2317853, RGD:4775206, RGD:1580276

NCBI chr 8:123,151,510...123,159,679
Ensembl chr 8:123,151,515...123,159,669

G

cytochrome b-245, beta polypeptide

Protein:increased expression:brain
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:16685210 PMID:21593737 PMID:27659729 PMID:27847271 PMID:32147540 More...

NCBI chr X:9,301,493...9,354,005
Ensembl chr X:9,301,491...9,354,010

G

cytochrome P450, family 11, subfamily a, polypeptide 1

mRNA:increased expression:hypothalamus

RGD

NCBI chr 9:57,905,307...57,934,314
Ensembl chr 9:57,913,694...57,934,306

G

steroid-11-beta-hydroxylase

mRNA:decreased expression:hypothalamus, cerebellum, cortex (rat)

RGD

NCBI chr15:74,706,741...74,713,492
Ensembl chr15:74,705,974...74,713,492

G

cytochrome P450, family 11, subfamily b, polypeptide 2

DNA:transition:5' utr:-344C>T (human)
ClinVar Annotator: match by term: Aldosterone to renin ratio, increased
mRNA:increased expression:brainstem, hippocampus, cortex (rat)

PMID:12213905 PMID:12788845 PMID:17003099 PMID:10024332 PMID:18495825 More...

RGD:4891152, RGD:2307304, RGD:4891156

NCBI chr15:74,722,467...74,728,080
Ensembl chr15:74,722,859...74,728,167

G

cytochrome P450, family 19, subfamily a, polypeptide 1

mRNA:decreased expression:ovary (rat)

RGD

NCBI chr 9:54,073,221...54,175,448
Ensembl chr 9:54,073,221...54,175,394

G

cytochrome P450, family 1, subfamily a, polypeptide 1

treatment

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:20634294 PMID:22995157 PMID:20634294 PMID:31489946 PMID:23528973 More...

RGD:7257731, RGD:401793758, RGD:401793732, RGD:401793709

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

cytochrome P450, family 1, subfamily b, polypeptide 1

treatment

RGD

NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490

G

cytochrome P450, family 2, subfamily c, polypeptide 52, pseudogene

NCBI chr19:38,965,106...38,992,071
Ensembl chr19:38,965,091...38,991,733

G

cytochrome P450, family 2, subfamily c, polypeptide 55

RGD

PMID:19669737 PMID:18829737

RGD:6903909, RGD:6903915

NCBI chr19:38,995,384...39,031,134
Ensembl chr19:38,995,463...39,031,137

G

cytochrome P450, family 2, subfamily c, polypeptide 65

associated with Diabetes Mellitus, Insulin-Dependent; DNA:polymorphism:cds:I359L (human)

PMID:17305793 PMID:19669737

RGD:2307150 RGD:6903909

NCBI chr19:39,049,450...39,082,392
Ensembl chr19:39,049,459...39,082,388

G

cytochrome P450, family 2, subfamily j, polypeptide 6

susceptibility

DNA:SNP

RGD

PMID:17286575 PMID:20501636

RGD:1625379, RGD:7243136

NCBI chr 4:96,404,375...96,449,835
Ensembl chr 4:96,404,375...96,441,898

G

cytochrome P450, family 2, subfamily j, polypeptide 9

susceptibility

DNA:SNP

PMID:17286575 PMID:20501636

RGD:1625379 RGD:7243136

NCBI chr 4:96,456,661...96,480,748
Ensembl chr 4:96,456,666...96,479,815

G

cytochrome P450, family 2, subfamily r, polypeptide 1

DNA:SNP:CDS: rs12794714 (human)
DNA:SNP:CDS:rs12794714 (human)
DNA:SNP:CDS:rs10741657|rs12794714 (human)
DNA:SNP:CDS:rs1993116|rs10741657 (human)

RGD

PMID:34906413 PMID:24974252 PMID:28760944 PMID:30192652

RGD:401900724, RGD:401901148, RGD:401901082, RGD:401901076

NCBI chr 7:114,149,358...114,162,283
Ensembl chr 7:114,148,917...114,162,207

G

cytochrome P450, family 4, subfamily a, polypeptide 10

CTD Direct Evidence: marker/mechanism
mRNA:decreased expression:kidney cortex

CTD
RGD

PMID:16691295 PMID:18952718 PMID:16339392

RGD:2303381, RGD:2303383

NCBI chr 4:115,375,484...115,390,846
Ensembl chr 4:115,375,461...115,390,846

G

cytochrome P450, family 4, subfamily a, polypeptide 12B

mRNA:decreased expression:kidney cortex

RGD

PMID:18952718 PMID:16339392

RGD:2303381, RGD:2303383

NCBI chr 4:115,268,821...115,296,231
Ensembl chr 4:115,268,821...115,296,231

G

cytochrome P450, family 4, subfamily f, polypeptide 14

mRNA:increased expression:kidney

RGD

NCBI chr17:33,122,331...33,136,353
Ensembl chr17:33,124,044...33,136,316

G

aspartyl-tRNA synthetase 2 (mitochondrial)

ClinVar Annotator: match by term: Hypertension

PMID:16199547 PMID:17384640 PMID:19592391 PMID:22843165 PMID:23065766 More...

NCBI chr 1:160,868,171...160,898,236
Ensembl chr 1:160,868,171...160,898,228

G

dopamine beta hydroxylase

resistance

mRNA:increased expression:heart, adrenal gland (rat)
DNA:polymorphism:5' utr:g.-2073C>T rs1989787 (human)

RGD

PMID:20596792 PMID:20814407

RGD:5129234, RGD:5129211

NCBI chr 2:27,055,519...27,073,216
Ensembl chr 2:27,055,245...27,073,212

G

dimethylarginine dimethylaminohydrolase 1

susceptibility

RGD

NCBI chr 3:145,464,447...145,600,032
Ensembl chr 3:145,464,430...145,600,032

G

deiodinase, iodothyronine, type II

susceptibility

RGD

NCBI chr12:90,691,326...90,705,812
Ensembl chr12:90,691,326...90,705,812

G

dopamine receptor D1

RGD

NCBI chr13:54,205,202...54,209,677
Ensembl chr13:54,205,202...54,209,724

G

dopamine receptor D2

DNA:polymorphism
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:11566895 PMID:15939106 PMID:11494094

RGD:1600905, RGD:1580874

NCBI chr 9:49,251,703...49,319,468
Ensembl chr 9:49,251,927...49,319,477

G

dopamine receptor D3

RGD

NCBI chr16:43,574,285...43,646,353
Ensembl chr16:43,574,389...43,643,295

G

dopamine receptor D5

RGD

NCBI chr 5:38,476,742...38,479,868
Ensembl chr 5:38,476,710...38,479,861

G

dual specificity phosphatase 1

mRNA, protein:increased expression:aorta

RGD

NCBI chr17:26,724,565...26,727,446
Ensembl chr17:26,724,564...26,781,102

G

dual specificity phosphatase 5

CTD Direct Evidence: marker/mechanism

NCBI chr19:53,517,576...53,530,240
Ensembl chr19:53,517,540...53,530,862

G

dynein light chain LC8-type 1

treatment

RGD

NCBI chr 5:115,435,129...115,438,995
Ensembl chr 5:115,435,169...115,439,058

G

endothelin converting enzyme 1

CTD Direct Evidence: marker/mechanism
mRNA,protein:increased expression,increased activity:kidney medulla

CTD
RGD

PMID:12566389 PMID:15126915 PMID:10894793

RGD:1580904, RGD:7244182

NCBI chr 4:137,589,548...137,692,540
Ensembl chr 4:137,589,548...137,692,540

G

endothelin 1

protein:increased secretion:plasma (rat)
CTD Direct Evidence: marker/mechanism
human gene in a rat model
associated with Diabetic Nephropathies;protein:increased secretion:plasma
DNA:polymorphism:exon:p.K198N (human)

CTD
RGD

PMID:7721406 PMID:8152482 PMID:8440307 PMID:10474778 PMID:10669576 More...

RGD:4144829, RGD:8661804, RGD:2313283, RGD:1625065

NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466

G

endothelin 2

mRNA:increased expression:leukocyte

RGD

PMID:15007037 PMID:10489105 PMID:10976780

RGD:1625402, RGD:1580917, RGD:1580916

NCBI chr 4:120,018,403...120,024,557
Ensembl chr 4:120,018,403...120,024,557

G

endothelin 3

CTD Direct Evidence: marker/mechanism

NCBI chr 2:174,602,412...174,625,835
Ensembl chr 2:174,602,412...174,625,835

G

endothelin receptor type A

associated with Uremia
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:12600921 PMID:20144075 PMID:14616768

RGD:4892284, RGD:1580950

NCBI chr 8:78,389,658...78,451,081
Ensembl chr 8:78,389,660...78,451,093

G

endothelin receptor type B

associated with Uremia

RGD

PMID:20144075 PMID:10749572

RGD:4892284, RGD:628518

NCBI chr14:104,052,055...104,081,764
Ensembl chr14:104,052,061...104,081,838

G

epidermal growth factor receptor

mRNA, protein:increased expression:renal cortex

RGD

NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158

G

egl-9 family hypoxia-inducible factor 1

RGD

NCBI chr 8:125,635,325...125,676,063
Ensembl chr 8:125,635,326...125,676,063

G

eukaryotic translation initiation factor 4, gamma 2

mRNA:increased expression:heart left ventricle

RGD

NCBI chr 7:110,667,192...110,682,237
Ensembl chr 7:110,666,957...110,682,237

G

elastin

CTD Direct Evidence: marker/mechanism

NCBI chr 5:134,731,449...134,776,300
Ensembl chr 5:134,731,447...134,776,177

G

elastin microfibril interfacer 1

RGD

NCBI chr 5:31,070,729...31,078,623
Ensembl chr 5:31,070,746...31,078,621

G

endoglin

mRNA:decreased expression:kidney (rat)

RGD

NCBI chr 2:32,536,607...32,572,681
Ensembl chr 2:32,536,607...32,572,681

G

enolase 1, alpha non-neuron

RGD

NCBI chr 4:150,321,165...150,333,336
Ensembl chr 4:150,321,178...150,333,336

G

enolase 2, gamma neuronal

severity

protein:increased expression:serum

RGD

NCBI chr 6:124,737,018...124,746,489
Ensembl chr 6:124,737,016...124,746,636

G

ectonucleoside triphosphate diphosphohydrolase 2

RGD

NCBI chr 2:25,285,886...25,291,335
Ensembl chr 2:25,285,886...25,291,333

G

E1A binding protein p300

protein:increased expression:left ventricle (rat)

RGD

NCBI chr15:81,470,329...81,536,273
Ensembl chr15:81,469,552...81,536,278

G

epoxide hydrolase 2, cytoplasmic

susceptibility

DNA:missense mutation:cds:p.K55R (human)

RGD

PMID:11001943 PMID:21720266 PMID:19553349 PMID:20065888

RGD:1580987, RGD:5688733, RGD:5688730, RGD:5688727

NCBI chr14:66,321,821...66,361,971
Ensembl chr14:66,321,823...66,361,949

G

erythropoietin

CTD Direct Evidence: marker/mechanism

PMID:1516988 PMID:10694834

NCBI chr 5:137,481,282...137,484,078
Ensembl chr 5:137,481,282...137,531,504

G

erythropoietin receptor

susceptibility

induced by erythropoietin;

RGD

NCBI chr 9:21,870,193...21,874,915
Ensembl chr 9:21,870,193...21,874,802

G

endoplasmic reticulum aminopeptidase 1

CTD Direct Evidence: marker/mechanism

NCBI chr13:74,787,692...74,841,321
Ensembl chr13:74,787,687...74,841,320

G

estrogen receptor 2 (beta)

RGD

PMID:15167447 PMID:23608653 PMID:11799247

RGD:1581017, RGD:7364951, RGD:734949

NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033

G

coagulation factor XI

CTD Direct Evidence: marker/mechanism

NCBI chr 8:45,693,696...45,715,092
Ensembl chr 8:45,694,211...45,715,068

G

F11 receptor

susceptibility

DNA:SNPs: :rs790056, rs2774276 (human)

RGD

PMID:18067551 PMID:17420334

RGD:7488938, RGD:7488939

NCBI chr 1:171,265,129...171,292,161
Ensembl chr 1:171,265,103...171,292,171

G

coagulation factor XII (Hageman factor)

CTD Direct Evidence: marker/mechanism
ClinVar Annotator: match by term: Hypertension

PMID:6383834 PMID:16638441 PMID:25741868

NCBI chr13:55,565,771...55,574,617
Ensembl chr13:55,565,771...55,574,606

G

coagulation factor II thrombin receptor

RGD

NCBI chr13:95,738,288...95,754,974
Ensembl chr13:95,738,311...95,754,995

G

coagulation factor III

treatment

RGD

NCBI chr 3:121,517,186...121,528,701
Ensembl chr 3:121,517,186...121,528,697

G

coagulation factor VII

protein:increased activity:plasma (human)
protein:increased activity:plasma (rat)

RGD

PMID:10450539 PMID:8123879 PMID:812575

RGD:2312402, RGD:2312412, RGD:2312323

NCBI chr 8:13,075,499...13,085,809
Ensembl chr 8:13,076,034...13,085,809

G

fatty acid binding protein 1, liver

possibly associated with arteriosclerosis (MeSH:D001161)

RGD

NCBI chr 6:71,176,863...71,182,018
Ensembl chr 6:71,176,811...71,182,007

G

fatty acid binding protein 3, muscle and heart

susceptibility

DNA:SNPs

RGD

NCBI chr 4:130,202,531...130,209,256
Ensembl chr 4:130,202,388...130,209,256

G

Fas associated via death domain

treatment

RGD

NCBI chr 7:144,132,060...144,136,178
Ensembl chr 7:144,131,055...144,136,200

G

fatty acid desaturase 1

RGD

NCBI chr19:10,160,245...10,174,238
Ensembl chr19:10,160,252...10,174,241

G

fumarylacetoacetate hydrolase

mRNA:decreased expression:kidney

RGD

NCBI chr 7:84,234,367...84,255,150
Ensembl chr 7:84,234,367...84,255,930

G

fibrillin 1

protein:increased expression:renal glomerulus (rat)

RGD

NCBI chr 2:125,142,514...125,348,417
Ensembl chr 2:125,142,514...125,349,913

G

fibroblast growth factor 2

associated with Aortic Coarctation

RGD

NCBI chr 3:37,402,616...37,464,255
Ensembl chr 3:37,402,495...37,464,257

G

fibroblast growth factor 21

CTD Direct Evidence: therapeutic

NCBI chr 7:45,263,314...45,264,914
Ensembl chr 7:45,263,310...45,264,914

G

flavin containing monooxygenase 3

no_association

associated with trimethylaminuria, OMIM:602079

RGD

PMID:16324215 PMID:9536088

RGD:1626466, RGD:1626461

NCBI chr 1:162,781,368...162,812,097
Ensembl chr 1:162,781,369...162,812,097

G

fibronectin 1

CTD Direct Evidence: marker/mechanism
mRNA:increased expression:kidney (SHRSP/A3N rat)

CTD
RGD

PMID:11682445 PMID:17324946 PMID:11907153 PMID:11682445

RGD:28912746, RGD:30296650

NCBI chr 1:71,624,632...71,692,439
Ensembl chr 1:71,624,679...71,692,359

G

fibronectin type III domain containing 5

CTD Direct Evidence: therapeutic

NCBI chr 4:129,030,672...129,038,386
Ensembl chr 4:129,030,477...129,038,386

G

FBJ osteosarcoma oncogene

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:12044476 PMID:24039778 PMID:16696897

NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047

G

forkhead box P3

treatment

RGD

NCBI chr X:7,445,915...7,461,482
Ensembl chr X:7,439,883...7,461,484

G

FTO alpha-ketoglutarate dependent dioxygenase

associated with Obesity
DNA:SNP:intron:rs9302652 (human)

RGD

PMID:31801409 PMID:20031594

RGD:329812016, RGD:329901765

NCBI chr 8:92,039,995...92,395,061
Ensembl chr 8:92,040,153...92,395,067

G

FXYD domain-containing ion transport regulator 2

CTD Direct Evidence: marker/mechanism

NCBI chr 9:45,311,007...45,321,576
Ensembl chr 9:45,310,967...45,321,576

G

gamma-aminobutyric acid type B receptor subunit 1

mRNA:increased expression:brain

RGD

NCBI chr17:37,356,888...37,385,197
Ensembl chr17:37,356,858...37,385,959

G

glutamate decarboxylase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 2:70,392,109...70,432,358
Ensembl chr 2:70,383,416...70,432,358

G

galanin and GMAP prepropeptide

mRNA:decreased expression:paraventricular hypothalamic nucleus, solitary tract nucleus
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:10818254 PMID:15275958

NCBI chr19:3,459,915...3,464,544
Ensembl chr19:3,459,915...3,464,544

G

GATA binding protein 5

susceptibility

DNA:SNPs:intron, exon:rs6061245,rs6587239 (human)

RGD

NCBI chr 2:179,966,881...179,977,296
Ensembl chr 2:179,966,926...179,976,492

G

glucagon

CTD Direct Evidence: marker/mechanism

NCBI chr 2:62,304,874...62,313,997
Ensembl chr 2:62,304,874...62,313,994

G

GTP cyclohydrolase 1

treatment
sexual_dimorphism

CTD Direct Evidence: marker/mechanism
mRNA:decreased expression:aorta
DNA:SNV:3' UTR: 59038C>T (rs841, +243C>T) (human)

CTD
RGD

PMID:12855421 PMID:12925450 PMID:33857222 PMID:15167268 PMID:12623977 More...

RGD:401700397, RGD:401700394, RGD:329970288, RGD:329961330, RGD:329961329

NCBI chr14:47,391,352...47,426,870
Ensembl chr14:47,391,352...47,426,870

G

glucokinase

susceptibility

RGD

NCBI chr11:5,850,816...5,900,081
Ensembl chr11:5,850,820...5,900,081

G

glutamate-cysteine ligase, catalytic subunit

CTD Direct Evidence: marker/mechanism

NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767

G

growth hormone secretagogue receptor

associated with Obesity

RGD

NCBI chr 3:27,425,500...27,433,384
Ensembl chr 3:27,425,500...27,432,159

G

gap junction protein, alpha 1

treatment

CTD Direct Evidence: marker/mechanism|therapeutic

CTD
RGD

PMID:16448880 PMID:36720419 PMID:16448880 PMID:23719203

RGD:7207810, RGD:8662439

NCBI chr10:56,253,297...56,266,519
Ensembl chr10:56,253,426...56,278,609

G

gap junction protein, alpha 4

CTD Direct Evidence: marker/mechanism

NCBI chr 4:127,205,213...127,207,832
Ensembl chr 4:127,205,214...127,207,832

G

gap junction protein, alpha 5

treatment

CTD Direct Evidence: marker/mechanism
protein:decreased expression:artery endothelium

CTD
RGD

PMID:19109587 PMID:19686729 PMID:11821709

RGD:7207417, RGD:7207848

NCBI chr 3:96,939,718...96,960,950
Ensembl chr 3:96,812,009...96,984,732

G

gap junction protein, gamma 1

CTD Direct Evidence: therapeutic

NCBI chr11:102,690,303...102,710,512
Ensembl chr11:102,690,405...102,710,526

G

glucuronyl C5-epimerase

DNA:SNP: : rs3865014 (human)

RGD

NCBI chr 9:61,964,526...62,029,891
Ensembl chr 9:61,964,530...62,029,937

G

glucagon-like peptide 1 receptor

CTD Direct Evidence: marker/mechanism

NCBI chr17:31,120,841...31,155,484
Ensembl chr17:31,120,791...31,159,765

G

G protein subunit alpha i2

treatment

RGD

PMID:27912212 PMID:15106810

RGD:13507308, RGD:13508592

NCBI chr 9:107,491,324...107,512,542
Ensembl chr 9:107,491,324...107,512,566

G

G protein subunit alpha i3

treatment

RGD

NCBI chr 3:108,014,591...108,053,468
Ensembl chr 3:108,014,596...108,053,462

G

GNAS complex locus

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:9506701 PMID:12215464 PMID:15118671

RGD:1580404, RGD:1331525

NCBI chr 2:174,126,113...174,188,537
Ensembl chr 2:174,126,113...174,188,537

G

guanine nucleotide binding protein (G protein), beta 3

no_association
susceptibility

DNA:polymorphism: :multiple (human)
CTD Direct Evidence: marker/mechanism
DNA:SNP:cds: 825C>T (human)
DNA:SNP:cds:825C>T (human)

CTD
RGD

PMID:15961981 PMID:16141801 PMID:16908025 PMID:11230982 PMID:10526907

RGD:2313206, RGD:1580408, RGD:1580410

NCBI chr 6:124,811,203...124,817,238
Ensembl chr 6:124,811,203...124,817,238

G

gonadotropin releasing hormone 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:67,982,717...67,986,889
Ensembl chr14:67,982,630...67,986,888

G

glycoprotein 1b, alpha polypeptide

CTD Direct Evidence: marker/mechanism

NCBI chr11:70,529,928...70,534,812
Ensembl chr11:70,529,948...70,532,862

G

glutathione peroxidase 1

treatment

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:21593737 PMID:17198913 PMID:31572179 PMID:21210316 PMID:23752977

RGD:1600704, RGD:329956417, RGD:11353777, RGD:11352825

NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542

G

glutathione peroxidase 3

treatment
susceptibility

DNA:SNP: : rs3828599 (human)
DNA:SNP: :rs3828599 (human)

RGD

PMID:23528973 PMID:21933611 PMID:32034489

RGD:401793732, RGD:401827166, RGD:401827127

NCBI chr11:54,793,680...54,801,213
Ensembl chr11:54,793,279...54,801,203

G

G protein-coupled receptor kinase 2

treatment

protein:increased expression:lymphocyte, vascular associated smooth muscle cell
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:11901213 PMID:10642272 PMID:23913704

RGD:1625788, RGD:13792716

NCBI chr19:4,336,029...4,356,356
Ensembl chr19:4,336,029...4,356,250

G

G protein-coupled receptor kinase 3

mRNA:increased expression:heart left ventricle, kidney (rat)

RGD

NCBI chr 5:113,058,344...113,163,518
Ensembl chr 5:113,058,348...113,163,657

G

G protein-coupled receptor kinase 5

mRNA:increased expression:heart left ventricle, kidney (rat)

RGD

NCBI chr19:60,877,995...61,084,406
Ensembl chr19:60,878,187...61,084,406

G

glycogen synthase kinase 3 beta

treatment

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:22982863 PMID:22982863

NCBI chr16:37,909,363...38,066,446
Ensembl chr16:37,909,363...38,066,446

G

glutathione reductase

treatment

RGD

PMID:17198913 PMID:23528973

RGD:1600704, RGD:401793732

NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191

G

glutathione S-transferase, alpha 1 (Ya)

CTD Direct Evidence: marker/mechanism

NCBI chr 9:78,137,951...78,149,965
Ensembl chr 9:78,137,938...78,149,966

G

glutathione S-transferase, mu 1

mRNA:decreased expression:kidney (rat)

RGD

NCBI chr 3:107,919,566...107,925,289
Ensembl chr 3:107,919,571...107,925,289

G

glutathione S-transferase, mu 2

treatment

mRNA:decreased expression:kidney (rat)

RGD

PMID:18008142 PMID:23528973 PMID:12624007

RGD:2302178, RGD:401793732, RGD:631154

NCBI chr 3:107,889,018...107,893,736
Ensembl chr 3:107,889,018...107,893,769

G

glutathione S-transferase, mu 3

treatment

RGD

NCBI chr 3:107,871,019...107,876,484
Ensembl chr 3:107,871,012...107,876,599

G

glutathione S-transferase, pi 1

CTD Direct Evidence: marker/mechanism

NCBI chr19:4,085,411...4,087,912
Ensembl chr19:4,085,407...4,087,985

G

glutathione S-transferase, theta 1

associated with scleroderma, systemic;DNA:deletion: :
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:22228705 PMID:11477481 PMID:32034489

RGD:5490587, RGD:401827127

NCBI chr10:75,619,647...75,634,418
Ensembl chr10:75,619,647...75,634,418

G

guanylate cyclase 1, soluble, alpha 1

CTD Direct Evidence: marker/mechanism

NCBI chr 3:81,999,734...82,053,253
Ensembl chr 3:81,999,734...82,053,096

G

histocompatibility 2, class II antigen A, alpha

DNA:polymorphisms (human)

RGD

NCBI chr17:34,501,718...34,506,797
Ensembl chr17:34,501,718...34,506,797

G

H2A.X variant histone

treatment

RGD

NCBI chr 9:44,246,012...44,247,374
Ensembl chr 9:44,245,991...44,247,374

G

hepatitis A virus cellular receptor 1

protein:increased expression:urine

RGD

NCBI chr11:46,630,644...46,670,405
Ensembl chr11:46,625,907...46,670,405

G

histone deacetylase 6

protein:increased expression, activity:heart:

RGD

NCBI chr X:7,796,355...7,814,284
Ensembl chr X:7,796,359...7,814,128

G

histone deacetylase 8

protein:decreased expression:heart (mouse, rat)

RGD

NCBI chr X:101,328,244...101,549,005
Ensembl chr X:101,328,245...101,548,965

G

hepatocyte growth factor

susceptibility

DNA:polymorphism:intron13:C/A

PMID:15127882 PMID:15127882

RGD:1642064, RGD:1642064

NCBI chr 5:16,758,493...16,827,448
Ensembl chr 5:16,758,493...16,825,150

G

hypoxia inducible factor 1, alpha subunit

Hypertension, Pregnancy-Induced;mRNA, protein:increased expression:placenta
CTD Direct Evidence: therapeutic
protein:increased expression:brain
associated with Hypercholesterolemia;protein:increased expression:aorta

CTD
RGD

PMID:22349312 PMID:15862159 PMID:16955051 PMID:11882589

RGD:1626322, RGD:1626317, RGD:1626330

NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304

G

hexokinase 2

treatment

RGD

NCBI chr 6:82,702,004...82,751,437
Ensembl chr 6:82,702,006...82,751,435

G

high mobility group box 1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:148,983,512...148,989,867
Ensembl chr 5:148,983,512...149,121,299

G

heme oxygenase 1

susceptibility
treatment

CTD Direct Evidence: marker/mechanism|therapeutic

CTD
RGD

PMID:16959961 PMID:22349312 PMID:22352330 PMID:12872043 PMID:20836698 More...

RGD:1598400, RGD:10755717, RGD:1580453

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

G

haptoglobin

susceptibility
onset

DNA:polymorphism
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:16597321 PMID:7606649 PMID:23401751 PMID:8228210

RGD:1626351, RGD:7241867, RGD:1626352

NCBI chr 8:110,301,760...110,305,804
Ensembl chr 8:110,301,760...110,305,804

G

histamine receptor H2

CTD Direct Evidence: marker/mechanism

NCBI chr13:54,345,990...54,390,201
Ensembl chr13:54,346,148...54,390,199

G

histamine receptor H3

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:9050021 PMID:9050021

NCBI chr 2:179,741,258...179,746,264
Ensembl chr 2:179,741,258...179,746,281

G

hydroxysteroid 11-beta dehydrogenase 1

susceptibility

CTD Direct Evidence: marker/mechanism
DNA:SNP:5'utr: (rs846910) (human)

CTD
RGD

PMID:9683905 PMID:15199296 PMID:21786805 PMID:15452033

NCBI chr 1:192,903,917...192,946,345
Ensembl chr 1:192,903,942...192,946,383

G

hydroxysteroid 11-beta dehydrogenase 2

apparent mineralocorticoid excess syndrome, OMIM:218030
CTD Direct Evidence: marker/mechanism
associated with Diabetes Mellitus, Experimental;mRNA:decreased expression:kidney

CTD
RGD

PMID:7670488 PMID:9683905 PMID:9707624 PMID:11082157 PMID:9683587 More...

RGD:1625078, RGD:13800514, RGD:2308925

NCBI chr 8:106,245,378...106,250,620
Ensembl chr 8:106,245,387...106,250,620

G

hydroxysteroid (17-beta) dehydrogenase 4

mRNA:decreased expression:renal cortex (rat)

RGD

NCBI chr18:50,261,268...50,329,337
Ensembl chr18:50,261,268...50,329,336

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1

susceptibility

DNA:polymorphism:exon
mRNA:decreased expression:ovary (rat)

PMID:19228890 PMID:12054649

RGD:4761326, RGD:1626438

NCBI chr 3:98,749,672...98,767,110
Ensembl chr 3:98,759,510...98,767,110

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2

mRNA:decreased expression:ovary (rat)

RGD

NCBI chr 3:98,618,423...98,631,859
Ensembl chr 3:98,616,571...98,631,859

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 6

mRNA:increased expression:hypothalamus (rat)

RGD

NCBI chr 3:98,712,820...98,721,759
Ensembl chr 3:98,712,820...98,721,759

G

heat shock protein 8

mRNA: increased expression: leukocyte

RGD

NCBI chr 9:40,712,572...40,716,498
Ensembl chr 9:40,712,280...40,721,383

G

heat shock protein 1 (chaperonin)

mRNA:increased expression:brain, blood vessel

RGD

PMID:15729290 PMID:18948349

RGD:1624213, RGD:10402862

NCBI chr 1:55,116,992...55,127,402
Ensembl chr 1:55,116,994...55,127,402

G

perlecan (heparan sulfate proteoglycan 2)

mRNA:increased expression:aorta

RGD

NCBI chr 4:137,196,062...137,297,941
Ensembl chr 4:137,196,080...137,297,941

G

5-hydroxytryptamine (serotonin) receptor 1B

protein:increased expression:aorta

RGD

NCBI chr 9:81,510,344...81,515,885
Ensembl chr 9:81,510,344...81,515,881

G

5-hydroxytryptamine (serotonin) receptor 2A

susceptibility
no_association

DNA:polymorphism: :102T>C
DNA:polymorphism: :g.102T>C

RGD
GAD

PMID:11378836 PMID:15118671 PMID:15659047

RGD:1624375, RGD:1331525, RGD:1624371

NCBI chr14:74,878,314...74,944,299
Ensembl chr14:74,878,280...74,946,934

G

5-hydroxytryptamine (serotonin) receptor 2B

CTD Direct Evidence: marker/mechanism

NCBI chr 1:86,025,268...86,043,960
Ensembl chr 1:86,026,748...86,039,692

G

HtrA serine peptidase 1

associated with Macular Degeneration; DNA:snp:cds:g.102C>T (rs1049331) (human)

RGD

NCBI chr 7:130,537,933...130,587,388
Ensembl chr 7:130,537,841...130,587,390

G

intercellular adhesion molecule 1

associated with Diabetes Mellitus, Non-Insulin-Dependent;protein:increased expression:serum
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:12149661 PMID:12425201 PMID:18619052

NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113

G

immediate early response 3

CTD Direct Evidence: marker/mechanism

NCBI chr17:36,132,605...36,133,803
Ensembl chr17:36,132,576...36,133,815

G

insulin-like growth factor 1

severity

mRNA:increased expression:aorta (rat)
CTD Direct Evidence: marker/mechanism|therapeutic

CTD
RGD

PMID:19502719 PMID:22228705 PMID:16431135 PMID:8418983 PMID:15996002

RGD:1598427, RGD:12904968, RGD:1580474

NCBI chr10:87,694,127...87,772,909
Ensembl chr10:87,694,127...87,772,904

G

insulin-like growth factor I receptor

protein:increased expression:aorta:

RGD

NCBI chr 7:67,601,486...67,883,416
Ensembl chr 7:67,602,575...67,883,416

G

insulin-like growth factor binding protein 2

mRNA, protein:decreased expression:liver, plasma

RGD

NCBI chr 1:72,863,650...72,891,633
Ensembl chr 1:72,863,662...72,891,633

G

inhibitor of kappaB kinase beta

treatment

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:27659729 PMID:32147540 PMID:19246475

NCBI chr 8:23,149,228...23,196,605
Ensembl chr 8:23,149,228...23,196,605

G

interleukin 10

RGD

NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711

G

interleukin 17A

protein:increased expression:blood serum (human)

RGD

NCBI chr 1:20,801,129...20,804,720
Ensembl chr 1:20,801,129...20,804,720

G

interleukin 1 beta

associated with Obesity;protein:increased expression:plasma
CTD Direct Evidence: marker/mechanism
mRNA, protein:increased expression:aorta, plasma

CTD
RGD

PMID:27292124 PMID:27659729 PMID:27847271 PMID:32147540 PMID:32165127 More...

RGD:1626638, RGD:7175338, RGD:1626635

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 1 receptor antagonist

susceptibility

DNA:polymorphisms

RGD

PMID:11840488 PMID:11585563

RGD:1626667, RGD:1626668

NCBI chr 2:24,226,872...24,241,503
Ensembl chr 2:24,226,865...24,241,506

G

interleukin 6

susceptibility

associated with end stage renal disease; DNA:polymorphisms:promoter: -174G>C (human)
protein:increased expression:blood serum (human)
CTD Direct Evidence: marker/mechanism
associated with Diabetes Mellitus, Non-Insulin-Dependent; protein:increased expression:extracellular space (human)

CTD
RGD

PMID:27292124 PMID:27659729 PMID:27847271 PMID:32147540 PMID:32165127 More...

RGD:1580485, RGD:329955577, RGD:2307283

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

interleukin 6 receptor, alpha

severity

Hypertension, Pregnancy-Induced;protein:increased expression:serum

RGD

NCBI chr 3:89,776,631...89,820,503
Ensembl chr 3:89,771,366...89,820,503

G

interleukin 6 signal transducer

severity

Hypertension, Pregnancy-Induced;protein:increased expression:serum

RGD

NCBI chr13:112,600,604...112,643,394
Ensembl chr13:112,600,604...112,646,620

G

inositol polyphosphate phosphatase-like 1

DNA:SNPs: :rs2276047,snp8,rs9886(human)
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:15220217 PMID:15220217

NCBI chr 7:101,471,839...101,487,419
Ensembl chr 7:101,471,839...101,487,436

G

insulin II

CTD Direct Evidence: marker/mechanism
CTD Direct Evidence: marker/mechanism|therapeutic

CTD
RGD

PMID:9719048 PMID:18360027 PMID:29211853 PMID:9095092

NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118

G

inversin

associated with nephronophthisis 2;

RGD

NCBI chr 4:48,279,707...48,431,956
Ensembl chr 4:48,279,760...48,431,954

G

integrin alpha 9

susceptibility

DNA:SNP: :rs155524(human)

RGD

NCBI chr 9:118,435,777...118,730,071
Ensembl chr 9:118,435,758...118,730,071

G

integrin alpha V

protein:increased expression:artery

RGD

NCBI chr 2:83,554,796...83,637,261
Ensembl chr 2:83,554,741...83,637,260

G

integral membrane protein 2B

CTD Direct Evidence: marker/mechanism

NCBI chr14:73,599,666...73,622,729
Ensembl chr14:73,599,666...73,622,729

G

jun proto-oncogene

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:24039778 PMID:11358932

NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459

G

potassium voltage-gated channel, shaker-related subfamily, member 3

protein:increased activity:T cell (human)

RGD

NCBI chr 3:106,943,486...106,947,223
Ensembl chr 3:106,943,485...106,945,386

G

potassium voltage-gated channel, shaker-related subfamily, member 5

mRNA:increased expression:heart

RGD

NCBI chr 6:126,509,514...126,512,518
Ensembl chr 6:126,509,514...126,512,375

G

potassium voltage-gated channel, shaker-related subfamily, beta member 1

mRNA:increased expression:aorta, arteries (rat)

RGD

NCBI chr 3:64,856,636...65,285,643
Ensembl chr 3:64,856,617...65,285,644

G

potassium inwardly-rectifying channel, subfamily J, member 1

CTD Direct Evidence: marker/mechanism

NCBI chr 9:32,283,714...32,310,493
Ensembl chr 9:32,283,789...32,310,493

G

potassium inwardly rectifying channel, subfamily J, member 11

RGD

NCBI chr 7:45,746,545...45,750,215
Ensembl chr 7:45,743,377...45,750,188

G

potassium inwardly-rectifying channel, subfamily J, member 8

RGD

NCBI chr 6:142,510,563...142,517,340
Ensembl chr 6:142,510,563...142,517,340

G

potassium large conductance calcium-activated channel, subfamily M, beta member 1

CTD Direct Evidence: marker/mechanism
mRNA, protein:increased expression:aorta, mesenteric artery

CTD
RGD

PMID:17700361 PMID:16293791 PMID:16814121 PMID:14551242

RGD:1581718, RGD:10412046, RGD:1298970

NCBI chr11:33,912,955...33,923,641
Ensembl chr11:33,913,013...33,923,641

G

potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4

ameliorates

mRNA, protein:increased expression:CD4-positive, alpha-beta T cell (human)
associated with Cardiac Fibrosis
protein:increased activity:T cell (human)

RGD

PMID:26502942 PMID:25715999 PMID:24524604

RGD:329955577, RGD:401794570, RGD:401794566

NCBI chr 7:24,069,750...24,084,635
Ensembl chr 7:24,069,688...24,086,115

G

potassium voltage-gated channel, subfamily Q, member 1

DNA:deletion:exon (rat)

RGD

NCBI chr 7:142,660,614...142,980,787
Ensembl chr 7:142,660,099...142,980,779

G

kinase insert domain protein receptor

treatment

DNA:polymorphism:cds:p.H472Q(human)

RGD

PMID:15838270 PMID:20630084

RGD:5684418, RGD:8552374

NCBI chr 5:76,093,487...76,139,880
Ensembl chr 5:76,093,487...76,139,118

G

kinesin family member 6

susceptibility

DNA:SNP, haplotype: :rs20455 (p.W719R), rs6930913 (human)

RGD

NCBI chr17:49,922,121...50,216,875
Ensembl chr17:49,922,164...50,216,875

G

klotho

treatment

mRNA,protein:decreased expression:kidney:

RGD

PMID:10892340 PMID:21051829 PMID:23225045

RGD:1581732, RGD:10403063, RGD:10403062

NCBI chr 5:150,876,072...150,917,282
Ensembl chr 5:150,876,072...150,917,282

G

kallikrein 1

susceptibility
no_association

mRNA:decreased expression:kidney
DNA:polymorphisms
CTD Direct Evidence: therapeutic

PMID:14568997 PMID:15167446 PMID:15905889 PMID:15809361

RGD:1581751 RGD:1641795, RGD:1358144

NCBI chr 7:43,874,784...43,879,046
Ensembl chr 7:43,874,784...43,879,042

G

kallikrein 1-related peptidase b3

RGD

NCBI chr 7:43,847,615...43,851,775
Ensembl chr 7:43,847,615...43,851,776

G

kallikrein B, plasma 1

associated with Diabetes Mellitus, Type 1; protein:increased expression:plasma:

RGD

NCBI chr 8:45,719,725...45,747,872
Ensembl chr 8:45,719,726...45,747,896

G

kininogen 1

CTD Direct Evidence: marker/mechanism

NCBI chr16:22,876,970...22,900,828
Ensembl chr16:22,876,615...22,900,828

G

Kirsten rat sarcoma viral oncogene homolog

RGD

NCBI chr 6:145,162,425...145,197,631
Ensembl chr 6:145,162,425...145,195,965

G

kynureninase

RGD

NCBI chr 2:43,445,270...43,572,734
Ensembl chr 2:43,445,341...43,572,734

G

lactate dehydrogenase A

treatment

RGD

NCBI chr 7:46,491,698...46,505,051
Ensembl chr 7:46,490,899...46,505,051

G

leptin

DNA:SNPs: :
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:12050272 PMID:16827954 PMID:25205467 PMID:27226618 PMID:19204185 More...

RGD:5128788, RGD:5128597

NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876

G

leptin receptor

disease_progression

DNA:polymorphisms:exons
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:22949526 PMID:10999797 PMID:27465994

RGD:5129161, RGD:12911217

NCBI chr 4:101,574,393...101,676,375
Ensembl chr 4:101,574,601...101,672,549

G

lectin, galactose binding, soluble 3

treatment

RGD

NCBI chr14:47,611,317...47,623,624
Ensembl chr14:47,605,208...47,623,617

G

luteinizing hormone beta

CTD Direct Evidence: marker/mechanism

NCBI chr 7:45,070,370...45,071,278
Ensembl chr 7:45,070,244...45,071,321

G

lipase, hormone sensitive

gestational hypertension;DNA:polymorphism:promoter:-60C>G

RGD

NCBI chr 7:25,078,952...25,097,911
Ensembl chr 7:25,078,952...25,098,135

G

lipase, endothelial

RGD

NCBI chr18:75,072,393...75,095,380
Ensembl chr18:75,072,393...75,094,334

G

Cyp11b2 promoter

ClinVar Annotator: match by term: Aldosterone to renin ratio, increased

PMID:12213905 PMID:12788845 PMID:17003099

NCBI chr15:74,728,086...74,728,514

G

lysyl oxidase

RGD

NCBI chr18:52,649,132...52,662,939
Ensembl chr18:52,649,139...52,662,939

G

lipoprotein lipase

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:22228705 PMID:16132104

NCBI chr 8:69,333,207...69,359,584
Ensembl chr 8:69,333,143...69,360,100

G

low density lipoprotein receptor-related protein 2

protein:altered localization:apical plasma membrane

RGD

NCBI chr 2:69,254,679...69,416,373
Ensembl chr 2:69,254,684...69,416,409

G

lymphotoxin A

no_association

RGD

NCBI chr17:35,422,141...35,424,568
Ensembl chr17:35,422,141...35,424,327

G

lactotransferrin

CTD Direct Evidence: therapeutic

NCBI chr 9:110,848,360...110,871,834
Ensembl chr 9:110,848,339...110,871,835

G

microtubule-associated protein 1 light chain 3 alpha

RGD

NCBI chr 2:155,118,284...155,119,993
Ensembl chr 2:155,118,217...155,119,993

G

mitogen-activated protein kinase 8

RGD

NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115

G

MAS1 oncogene

associated with Sleep Apnea Syndromes

RGD

NCBI chr17:13,056,981...13,087,037
Ensembl chr17:13,059,966...13,087,030

G

melanocortin 2 receptor

CTD Direct Evidence: marker/mechanism

NCBI chr18:68,539,970...68,562,391
Ensembl chr18:68,539,978...68,562,391

G

mast cell protease 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:56,255,421...56,257,848
Ensembl chr14:56,255,428...56,257,841

G

malate dehydrogenase 1, NAD (soluble)

CTD Direct Evidence: marker/mechanism

NCBI chr11:21,506,692...21,521,934
Ensembl chr11:21,506,692...21,522,367

G

mitofusin 2

treatment

protein:decreased expression:aorta (rat)

RGD

PMID:27847271 PMID:25464244

RGD:12910764, RGD:13204764

NCBI chr 4:147,958,043...147,989,527
Ensembl chr 4:147,958,056...147,989,161

G

macrophage migration inhibitory factor (glycosylation-inhibiting factor)

RGD

NCBI chr10:75,695,187...75,696,111
Ensembl chr10:75,695,187...75,696,074

G

microRNA 145a

miRNA:increased expression:artery wall (human)

RGD

NCBI chr18:61,780,896...61,780,965
Ensembl chr18:61,780,896...61,780,965

G

microRNA 214

treatment

RNA:increased expression:kidney

PMID:30049682 PMID:30049682

RGD:38500245, RGD:38500245

NCBI chr 1:162,050,937...162,051,046
Ensembl chr 1:162,050,937...162,051,046

G

membrane metallo endopeptidase

treatment

RGD

NCBI chr 3:63,202,632...63,291,134
Ensembl chr 3:63,148,958...63,293,451

G

matrix metallopeptidase 1a (interstitial collagenase)

protein:decreased expression:renal glomerulus (human)

RGD

PMID:15363819 PMID:19506087

RGD:1582532, RGD:2312464

NCBI chr 9:7,464,141...7,476,870
Ensembl chr 9:7,464,141...7,476,857

G

matrix metallopeptidase 1b (interstitial collagenase)

protein:decreased expression:renal glomerulus (human)

PMID:15363819 PMID:19506087

RGD:1582532 RGD:2312464

NCBI chr 9:7,367,670...7,388,026
Ensembl chr 9:7,368,239...7,388,047

G

matrix metallopeptidase 2

mRNA, protein:increased expression:kidney
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:18836702 PMID:17977875 PMID:16840178

RGD:2290351, RGD:1582612

NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048

G

matrix metallopeptidase 7

treatment

RGD

PMID:19398663 PMID:19398663

RGD:9685347, RGD:9685347

NCBI chr 9:7,692,095...7,699,587
Ensembl chr 9:7,692,091...7,699,587

G

matrix metallopeptidase 9

susceptibility

protein:decreased expression:internal mammary artery
CTD Direct Evidence: marker/mechanism
associated with Aneurysm, Dissecting;DNA:polymorphism:promoter:-1562C>T

CTD
RGD

PMID:21051829 PMID:15363819 PMID:16780738 PMID:16840178 PMID:17977875

RGD:1582532, RGD:1642029, RGD:1582612, RGD:2290351

NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770

G

Mov10 RISC complex RNA helicase

susceptibility

DNA:SNP: :rs2932538(human)

RGD

NCBI chr 3:104,702,144...104,725,935
Ensembl chr 3:104,702,152...104,725,879

G

monooxygenase, DBH-like 2

CTD Direct Evidence: marker/mechanism

NCBI chr 6:40,855,728...40,864,428
Ensembl chr 6:40,855,728...40,864,428

G

msh homeobox 2

RGD

NCBI chr13:53,620,917...53,626,816
Ensembl chr13:53,620,920...53,627,110

G

mechanistic target of rapamycin kinase

protein:increased serine phosphorylation:kidney
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:19289642 PMID:23323219

NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140

G

myotrophin

RGD

PMID:12419325 PMID:12031792

RGD:632799, RGD:1581046

NCBI chr 6:35,485,759...35,516,823
Ensembl chr 6:35,485,841...35,516,823

G

5-methyltetrahydrofolate-homocysteine methyltransferase

RGD

NCBI chr13:12,196,217...12,273,090
Ensembl chr13:12,197,598...12,272,999

G

microsomal triglyceride transfer protein

onset

DNA:polymorphism:promoter:-493G>T

RGD

NCBI chr 3:137,795,616...137,849,179
Ensembl chr 3:137,795,615...137,850,729

G

myosin binding protein H

DNA:missense mutations:cds:p.I?T, p.R?K (rat)

RGD

NCBI chr 1:134,121,159...134,128,975
Ensembl chr 1:134,121,186...134,128,970

G

myeloid differentiation primary response gene 88

CTD Direct Evidence: marker/mechanism

NCBI chr 9:119,165,000...119,169,084
Ensembl chr 9:119,165,000...119,170,477

G

myosin, heavy polypeptide 7, cardiac muscle, beta

protein:decreased expression:heart left ventricle, arteriole
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:32147540 PMID:9686760

NCBI chr14:55,208,141...55,232,083
Ensembl chr14:55,208,141...55,232,083

G

myosin VI

protein:altered localization:renal proximal tubule, microvillus

RGD

NCBI chr 9:80,072,262...80,219,011
Ensembl chr 9:80,072,313...80,219,011

G

myogenic differentiation 1

mRNA:decreased expression:gastrocnemius

RGD

NCBI chr 7:46,025,898...46,028,516
Ensembl chr 7:46,025,898...46,028,523

G

neutrophil cytosolic factor 1

CTD Direct Evidence: marker/mechanism

PMID:16331104 PMID:17324946 PMID:19018797 PMID:32165127

NCBI chr 5:134,248,907...134,258,479
Ensembl chr 5:134,248,907...134,258,479

G

neutrophil cytosolic factor 2

protein:increased expression:heart left ventricle

RGD

NCBI chr 1:152,675,904...152,712,743
Ensembl chr 1:152,675,945...152,712,742

G

neural precursor cell expressed, developmentally down-regulated gene 4-like

CTD Direct Evidence: marker/mechanism

PMID:18524855 PMID:23348737

NCBI chr18:65,017,551...65,350,888
Ensembl chr18:65,020,776...65,350,899

G

nuclear factor, erythroid derived 2, like 2

treatment

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:32165127 PMID:23775684 PMID:23528973

RGD:10412717, RGD:401793732

NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985

G

nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha

treatment

RGD

NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432

G

nerve growth factor

RGD

NCBI chr 3:102,377,235...102,428,329
Ensembl chr 3:102,377,235...102,428,329

G

nerve growth factor receptor (TNFR superfamily, member 16)

DNA,protein:missense mutation:CDS:c.28G>A, p.A10T (rat strains: SHR/Izm, SHRSP/Izm, WKHT)

RGD

NCBI chr11:95,459,644...95,478,524
Ensembl chr11:95,459,644...95,478,561

G

NHERF family PDZ scaffold protein 1

RGD

NCBI chr11:115,054,138...115,072,009
Ensembl chr11:115,054,167...115,072,007

G

NHERF family PDZ scaffold protein 2

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:22228705 PMID:15311100

NCBI chr17:24,858,255...24,869,279
Ensembl chr17:24,858,260...24,869,301

G

nischarin

RGD

NCBI chr14:30,892,885...30,928,783
Ensembl chr14:30,892,887...30,938,903

G

nitric oxide synthase 1, neuronal

treatment

mRNA:decreased expression:bladder, penis

RGD

PMID:20494920 PMID:31489946 PMID:23201071 PMID:15913838 PMID:16093913 More...

RGD:5132600, RGD:401793758, RGD:7257668, RGD:1581142, RGD:1581141, RGD:1581143, RGD:1642127

NCBI chr 5:118,004,904...118,096,905
Ensembl chr 5:117,919,097...118,096,905

G

nitric oxide synthase 2, inducible

CTD Direct Evidence: marker/mechanism
protein:increased expression, increased activity:kidney

CTD
RGD

PMID:18605955 PMID:25101153 PMID:27292124 PMID:11702222 PMID:15773227

RGD:1298023, RGD:1580264

NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080

G

nitric oxide synthase 3, endothelial cell

treatment
no_association

associated with Pregnancy Complications
CTD Direct Evidence: marker/mechanism|therapeutic
DNA:duplication, snp:intron, cds:IVS4?-?+27, p.E298D (human)
DNA:snp:cds:p.E298D (human)
protein:decreased phosphorylation:brain

CTD
RGD

PMID:11457755 PMID:12947532 PMID:16331104 PMID:19008412 PMID:19407804 More...

RGD:2292113, RGD:401793758, RGD:13504683, RGD:13446414, RGD:1580278, RGD:1580271, RGD:1580282, RGD:4891993

NCBI chr 5:24,569,772...24,589,472
Ensembl chr 5:24,569,808...24,589,472

G

NADPH oxidase 1

ameliorates

RGD

NCBI chr X:132,987,170...133,038,455
Ensembl chr X:132,987,170...133,122,705

G

NADPH oxidase 4

protein:increased expression:aorta, vascular associated smooth muscle cell
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:27659729 PMID:27847271 PMID:32147540 PMID:18418428 PMID:26644237

RGD:2324669, RGD:11085830

NCBI chr 7:86,893,638...87,047,918
Ensembl chr 7:86,895,304...87,047,918

G

nephronophthisis 3 (adolescent)

associated with nephronophthisis;

RGD

NCBI chr 9:103,879,743...103,921,010
Ensembl chr 9:103,879,743...103,921,017

G

natriuretic peptide type A

protein:increased expression:plasma:
CTD Direct Evidence: marker/mechanism|therapeutic

CTD
MouseDO
RGD

PMID:2526952 PMID:7839143 PMID:8188982 PMID:9869009 PMID:12940879 More...

NCBI chr 4:148,085,179...148,086,531
Ensembl chr 4:148,085,179...148,086,536

G

natriuretic peptide type B

treatment
susceptibility

CTD Direct Evidence: marker/mechanism|therapeutic
DNA:repeats

CTD
RGD

PMID:9194512 PMID:19219041 PMID:24039778 PMID:30310171 PMID:32147540 More...

RGD:70484, RGD:5685657, RGD:1642191

NCBI chr 4:148,070,264...148,071,662
Ensembl chr 4:148,070,245...148,071,662

G

natriuretic peptide type C

severity

associated with Pregnancy Complications;protein:increased expression:plasma

RGD

PMID:11775888 PMID:12452325

RGD:1642292, RGD:1580150

NCBI chr 1:86,594,015...86,598,295
Ensembl chr 1:86,594,013...86,598,293

G

natriuretic peptide receptor 1

DNA:repeat:promoter: (rat)
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:20881240 PMID:12511524

NCBI chr 3:90,357,898...90,373,235
Ensembl chr 3:90,357,898...90,373,173

G

natriuretic peptide receptor 3

DNA:snp:promoter:g.-55C>A (human)

RGD

NCBI chr15:11,839,982...11,907,287
Ensembl chr15:11,839,982...11,907,373

G

neuroplastin

CTD Direct Evidence: marker/mechanism

NCBI chr 9:58,489,504...58,560,162
Ensembl chr 9:58,489,523...58,565,238

G

neuropeptide Y

DNA:missense mutation:cds:p.L7P (human)

RGD

PMID:15699473 PMID:18835922 PMID:11689216

RGD:1357410, RGD:10448968, RGD:1580177

NCBI chr 6:49,799,690...49,806,487
Ensembl chr 6:49,799,690...49,806,487

G

neuropeptide Y receptor Y1

RGD

NCBI chr 8:67,149,595...67,159,452
Ensembl chr 8:67,149,844...67,159,444

G

NAD(P)H dehydrogenase, quinone 1

treatment
susceptibility

DNA:SNP,haplotype:: p.P187S (rs1800566) (human)

PMID:25529925 PMID:21502369

RGD:401827819, RGD:11035215

NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838

G

nuclear receptor subfamily 2, group F, member 2

RGD

NCBI chr 7:70,001,694...70,016,494
Ensembl chr 7:70,001,692...70,016,483

G

nuclear receptor subfamily 3, group C, member 1

associated with fetal nutrition disorder
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:18434569 PMID:20659135 PMID:20674672 PMID:20659135

RGD:4892208, RGD:7174714

NCBI chr18:39,543,598...39,652,485
Ensembl chr18:39,543,598...39,652,474

G

nudix hydrolase 1

RGD

NCBI chr 5:140,307,375...140,323,892
Ensembl chr 5:140,307,411...140,323,892

G

8-oxoguanine DNA-glycosylase 1

susceptibility

DNA:SNP,haplotype::p.S326C (rs1052133) (human)

NCBI chr 6:113,303,959...113,311,149
Ensembl chr 6:113,303,933...113,312,029

G

oxidized low density lipoprotein (lectin-like) receptor 1

mRNA:increased expression:aorta (rat)
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:22352330 PMID:9494115

NCBI chr 6:129,456,113...129,484,312
Ensembl chr 6:129,462,207...129,484,128

G

OPA1, mitochondrial dynamin like GTPase

protein:increased expression:heart left ventricle (rat)

RGD

NCBI chr16:29,398,099...29,481,924
Ensembl chr16:29,398,152...29,473,702

G

ORAI calcium release-activated calcium modulator 1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:123,153,078...123,168,515
Ensembl chr 5:123,153,137...123,168,519

G

oxidative-stress responsive 1

CTD Direct Evidence: therapeutic

NCBI chr 9:119,067,498...119,154,475
Ensembl chr 9:119,067,498...119,151,493

G

oxytocin

CTD Direct Evidence: therapeutic
mRNA:decreased expression:paraventricular hypothalamic nucleus

CTD
RGD

PMID:9334988 PMID:18562099 PMID:18562099 PMID:16157794

RGD:2304105, RGD:2304174

NCBI chr 2:130,416,432...130,418,974
Ensembl chr 2:130,418,093...130,418,974

G

oxytocin receptor

mRNA:decreased expression:brainstem

RGD

NCBI chr 6:112,450,646...112,467,800
Ensembl chr 6:112,450,644...112,466,904

G

pregnancy-associated plasma protein A

associated with Pregnancy Complications, Cardiovascular;protein:decreased expression:serum

RGD

NCBI chr 4:65,041,993...65,276,776
Ensembl chr 4:65,042,411...65,275,746

G

platelet derived growth factor, B polypeptide

RGD

NCBI chr15:79,880,066...79,899,178
Ensembl chr15:79,880,075...79,899,178

G

platelet derived growth factor receptor, alpha polypeptide

RGD

NCBI chr 5:75,311,988...75,358,867
Ensembl chr 5:75,312,953...75,358,876

G

platelet derived growth factor receptor, beta polypeptide

protein:increased tyrosine phosphorylation:glomerulus

RGD

PMID:12047046 PMID:1657776

RGD:2292214, RGD:11080972

NCBI chr18:61,178,194...61,218,139
Ensembl chr18:61,178,222...61,218,133

G

placental growth factor

associated with Pregnancy Complications, Cardiovascular;mRNA:decreased expression:placenta

RGD

NCBI chr12:85,213,413...85,224,087
Ensembl chr12:85,213,409...85,224,564

G

phosphoinositide-3-kinase regulatory subunit 1

protein:decreased expression:ventricular myocyte (rat)

RGD

PMID:18300869 PMID:19015400

RGD:4108492, RGD:4108483

NCBI chr13:101,817,269...101,904,725
Ensembl chr13:101,817,071...101,904,725

G

peptidyl-prolyl cis/trans isomerase, NIMA-interacting 1

RGD

NCBI chr 9:20,563,335...20,575,008
Ensembl chr 9:20,563,391...20,577,880

G

polycystin 1, transient receptor potential channel interacting

ClinVar Annotator: match by term: Hypertension

PMID:11115377 PMID:12482949 PMID:16430766 PMID:17574468 PMID:17582161 More...

NCBI chr17:24,767,657...24,815,457
Ensembl chr17:24,768,808...24,815,482

G

pyruvate kinase, muscle

treatment

RGD

NCBI chr 9:59,563,859...59,586,655
Ensembl chr 9:59,563,651...59,586,658

G

plasminogen activator, tissue

CTD Direct Evidence: marker/mechanism

NCBI chr 8:23,247,655...23,272,864
Ensembl chr 8:23,247,743...23,272,860

G

phospholipase C, delta 1

protein:increased activity:aorta
protein:increased expression:aorta, arteriole, glomerulus

RGD

PMID:1313006 PMID:17198910

RGD:2300423, RGD:2300421

NCBI chr 9:118,900,595...118,922,570
Ensembl chr 9:118,900,595...118,922,570

G

pleckstrin homology domain containing, family A member 7

ameliorates

RGD

NCBI chr 7:115,722,722...115,907,617
Ensembl chr 7:115,722,720...115,907,611

G

plasminogen

CTD Direct Evidence: marker/mechanism

NCBI chr17:12,597,496...12,638,271
Ensembl chr17:12,597,495...12,638,272

G

phenylethanolamine-N-methyltransferase

no_association

DNA:snps:5' utr:g.-390G>A, g.-184G>A rs876493 (human)
protein:decreased activity:adrenal gland (rat)
DNA:snp:5' utr:g.-390G>A (human)

RGD

PMID:17645789 PMID:20378607 PMID:14553966

RGD:5130172, RGD:5130152, RGD:5130164

NCBI chr11:98,277,449...98,279,006
Ensembl chr11:98,277,276...98,279,007

G

pro-opiomelanocortin-alpha

CTD Direct Evidence: marker/mechanism|therapeutic

PMID:76749 PMID:187612 PMID:216942 PMID:323586 PMID:1316127 More...

NCBI chr12:4,004,945...4,010,643
Ensembl chr12:4,004,951...4,010,642

G

paraoxonase 1

DNA:SNP: :rs705379 (human)

RGD

NCBI chr 6:5,168,101...5,193,824
Ensembl chr 6:5,168,090...5,193,946

G

periostin, osteoblast specific factor

associated with Renal Insufficiency, Chronic; protein:increased expression:left ventricle:

RGD

NCBI chr 3:54,266,688...54,298,462
Ensembl chr 3:54,268,530...54,298,458

G

peroxisome proliferator activated receptor alpha

treatment

mRNA:increased expression:skeletal muscle
CTD Direct Evidence: marker/mechanism|therapeutic

CTD
RGD

PMID:16054168 PMID:19834340 PMID:19763017 PMID:31489946 PMID:15967866

RGD:2313778, RGD:401793758, RGD:1580222

NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020

G

peroxisome proliferator activated receptor gamma

human gene in a mouse model
CTD Direct Evidence: marker/mechanism|therapeutic
protein:decreased expression:rostral ventrolateral medulla (rat)

CTD
RGD

PMID:15199296 PMID:19666838 PMID:27292124 PMID:18316027 PMID:20404217 More...

RGD:2301864, RGD:7175297, RGD:1580690, RGD:2301888, RGD:1580684

NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360

G

pro-platelet basic protein

CTD Direct Evidence: marker/mechanism

PMID:6192689 PMID:15513305

NCBI chr 5:90,916,377...90,917,922
Ensembl chr 5:90,916,377...90,917,922

G

peptidylprolyl isomerase A

mRNA:increased expression:alveolar system (human)

NCBI chr11:6,365,867...6,369,817
Ensembl chr11:6,365,443...6,369,817

G

protein kinase, AMP-activated, gamma 2 non-catalytic subunit

ClinVar Annotator: match by term: Hypertension

PMID:25741868 PMID:28492532

NCBI chr 5:25,067,733...25,311,576
Ensembl chr 5:25,067,742...25,305,640

G

protein kinase, cAMP dependent regulatory, type I beta

RGD

NCBI chr 5:139,003,059...139,136,458
Ensembl chr 5:139,003,061...139,135,756

G

protein kinase C, alpha

RGD

NCBI chr11:107,824,213...108,237,360
Ensembl chr11:107,824,213...108,234,754

G

protein kinase C, beta

RGD

NCBI chr 7:121,888,327...122,233,625
Ensembl chr 7:121,887,974...122,233,625

G

protein kinase C, delta

protein:increased expression:heart, fibroblast
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:23973649 PMID:10756122 PMID:15792354

RGD:1642534, RGD:1581271

NCBI chr14:30,317,310...30,348,637
Ensembl chr14:30,317,311...30,348,167

G

protein kinase C, epsilon

RGD

NCBI chr17:86,472,631...86,965,347
Ensembl chr17:86,475,213...86,965,347

G

protein kinase, cGMP-dependent, type I

mRNA, protein:splice variant, alternative form:basilar artery

RGD

NCBI chr19:30,541,887...31,742,675
Ensembl chr19:30,541,889...31,742,433

G

prolactin releasing hormone receptor

DNA:SNP, missense mutation:promoter, cds:-62G>A, 914C>T (p.P305L) (human)

RGD

NCBI chr19:60,454,079...60,457,907
Ensembl chr19:60,455,170...60,456,742

G

protein C

CTD Direct Evidence: marker/mechanism

NCBI chr18:32,256,179...32,272,623
Ensembl chr18:32,256,179...32,272,623

G

phosphatase and tensin homolog

CTD Direct Evidence: marker/mechanism

NCBI chr19:32,734,977...32,803,560
Ensembl chr19:32,734,897...32,803,560

G

prostaglandin D2 synthase (brain)

protein:increased expression:serum, urine

RGD

NCBI chr 2:25,356,723...25,360,080
Ensembl chr 2:25,356,721...25,360,058

G

prostaglandin I2 (prostacyclin) synthase

susceptibility

mRNA:increased expression:aortic endothelial cell (rat)
DNA:repeat:promoter:g.-6(CCGCCAGCC)3-4 (human)
DNA:SNP:exon 8:g.1117C>A (rs6095558) (human)

RGD

PMID:12372404 PMID:18056786 PMID:10577996 PMID:17070428

RGD:1298040, RGD:401960082, RGD:401959586, RGD:401959383

NCBI chr 2:167,045,114...167,095,069
Ensembl chr 2:167,033,725...167,082,524

G

prostaglandin reductase 1

mRNA:decreased expression:rostral ventrolateral medulla, paraventricular nucleus of hypothalamus, nucleus of solitary tract (rat)

RGD

NCBI chr 4:58,965,590...58,987,131
Ensembl chr 4:58,965,439...58,987,119

G

prostaglandin-endoperoxide synthase 2

CTD Direct Evidence: marker/mechanism|therapeutic

CTD
RGD

PMID:14757778 PMID:15834289 PMID:20667508 PMID:22349312 PMID:15775781 More...

RGD:1581285, RGD:1580671

NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978

G

parathyroid hormone

protein:increased expression:serum (human)
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:1930854 PMID:23460043

NCBI chr 7:112,984,783...112,987,879
Ensembl chr 7:112,984,787...112,987,777

G

PTK2 protein tyrosine kinase 2

protein:increased expression:aorta

RGD

PMID:12732587 PMID:21068519

RGD:729831, RGD:10041072

NCBI chr15:73,076,951...73,297,192
Ensembl chr15:73,076,951...73,295,129

G

PTK2 protein tyrosine kinase 2 beta

susceptibility

DNA:polymorphism:promoter:-22A>G
protein:increased expression:aorta

RGD

PMID:18075463 PMID:21068519

RGD:2292575, RGD:10041072

NCBI chr14:66,390,706...66,518,549
Ensembl chr14:66,390,706...66,518,501

G

protein tyrosine phosphatase, non-receptor type 1

treatment

CTD Direct Evidence: therapeutic
associated with obesity

CTD
RGD

PMID:28899902 PMID:29859467 PMID:29562733

RGD:401976391, RGD:401976390

NCBI chr 2:167,772,670...167,821,305
Ensembl chr 2:167,773,977...167,821,305

G

protein tyrosine phosphatase receptor type C

ameliorates

associated with Cardiac Fibrosis

RGD

NCBI chr 1:137,990,601...138,103,491
Ensembl chr 1:137,990,599...138,103,446

G

protein tyrosine phosphatase receptor type D

treatment

DNA:SNP:enhancer: (rs10739150) (human)

RGD

NCBI chr 4:75,859,474...78,132,282
Ensembl chr 4:75,859,475...78,130,198

G

protein tyrosine phosphatase receptor type J

RGD

NCBI chr 2:90,260,100...90,411,102
Ensembl chr 2:90,260,098...90,410,991

G

protein tyrosine phosphatase receptor type U

susceptibility

RGD

NCBI chr 4:131,495,768...131,565,617
Ensembl chr 4:131,495,768...131,565,599

G

quinoid dihydropteridine reductase

protein:decreased expression:aorta smooth muscle (rat)

RGD

NCBI chr 5:45,591,374...45,607,571
Ensembl chr 5:45,591,363...45,607,578

G

RAD51 recombinase

treatment

RGD

NCBI chr 2:118,943,295...118,966,554
Ensembl chr 2:118,943,274...118,977,926

G

recombination activating 1

RGD

NCBI chr 2:101,468,597...101,479,877
Ensembl chr 2:101,468,627...101,479,846

G

ralA binding protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr17:66,155,410...66,192,750
Ensembl chr17:66,155,413...66,192,793

G

receptor (calcitonin) activity modifying protein 2

susceptibility

DNA:SNP:intron
mRNA, protein:increased expression:heart myocardium, aorta
associated with Pregnancy Complications

RGD

PMID:15797661 PMID:16450076 PMID:11600589

RGD:1642679, RGD:1625300, RGD:1642682

NCBI chr11:101,137,160...101,139,076
Ensembl chr11:101,136,854...101,150,372

G

RAS, guanyl releasing protein 3

RGD

NCBI chr17:75,742,849...75,836,049
Ensembl chr17:75,742,891...75,836,049

G

RNA binding protein, fox-1 homolog (C. elegans) 2

mRNA, protein:splice variant, increased expression:mesenteric artery (rat)

RGD

NCBI chr15:76,963,190...77,193,058
Ensembl chr15:76,963,190...77,191,204

G

retinol binding protein 4, plasma

sexual_dimorphism
ameliorates

protein:increased expression:blood serum (human)

RGD

PMID:20798476 PMID:21365528 PMID:25911613

RGD:329845596, RGD:329853304, RGD:329845871

NCBI chr19:38,105,068...38,113,769
Ensembl chr19:38,105,077...38,113,729

G

regenerating islet-derived 3 gamma

CTD Direct Evidence: marker/mechanism

NCBI chr 6:78,443,252...78,445,857
Ensembl chr 6:78,443,252...78,445,855

G

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:19018797 PMID:27659729 PMID:32147540 PMID:16840655

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

G

renin 1 structural

treatment

CTD Direct Evidence: marker/mechanism
protein:decreased activity:plasma (mouse)

CTD
RGD

PMID:45830 PMID:62162 PMID:998518 PMID:1071603 PMID:1149188 More...

RGD:1580697, RGD:401793709, RGD:6892655, RGD:6784501, RGD:1580671

NCBI chr 1:133,278,412...133,288,058
Ensembl chr 1:133,278,248...133,288,063

G

renin 2 tandem duplication of Ren1

CTD Direct Evidence: marker/mechanism

PMID:9595497 PMID:9869009 PMID:12512695 PMID:12586211

G

regulated endocrine-specific protein 18

RGD

NCBI chr 1:75,248,841...75,255,059
Ensembl chr 1:75,248,843...75,255,059

G

resistin

DNA:SNP:3' utr:*62A>G (human)

RGD

NCBI chr 8:3,705,770...3,709,818
Ensembl chr 8:3,705,770...3,710,110

G

ring finger and FYVE like domain containing protein

mRNA,protein:increased expression:heart

RGD

NCBI chr11:82,694,645...82,762,065
Ensembl chr11:82,693,275...82,762,036

G

regulator of G-protein signaling 2

CTD Direct Evidence: therapeutic

CTD
RGD

PMID:1798635 PMID:14608379 PMID:17986358

RGD:13524579, RGD:2289116

NCBI chr 1:143,875,076...143,879,887
Ensembl chr 1:143,875,076...143,879,899

G

regulator of G-protein signaling 4

treatment

RGD

NCBI chr 1:169,569,046...169,575,211
Ensembl chr 1:169,569,046...169,575,211

G

regulator of G-protein signaling 5

treatment

CTD Direct Evidence: therapeutic

CTD
RGD

PMID:1798635 PMID:21825230

NCBI chr 1:169,483,070...169,523,367
Ensembl chr 1:169,483,070...169,523,382

G

ras homolog family member A

protein:altered localization:mesenteric artery

RGD

NCBI chr 9:108,183,359...108,215,142
Ensembl chr 9:108,183,328...108,215,133

G

renalase, FAD-dependent amine oxidase

associated with Diabetes Mellitus Type 2; DNA:SNPs: : rs2296545,rs2576178 (human)
associated with kidney Failure,Chronic;DNA:SNPs: : rs2576178, rs10887800 (human)

RGD

PMID:21964580 PMID:21178975 PMID:21617193

RGD:7327172, RGD:7327174, RGD:7327173

NCBI chr19:33,115,140...33,369,695
Ensembl chr19:33,115,147...33,369,665

G

arginyl aminopeptidase (aminopeptidase B)

protein:increased expression:adrenal gland, neurohypophysis

RGD

PMID:9660082 PMID:3001599

RGD:2325942, RGD:2325950

NCBI chr 1:135,190,447...135,211,765
Ensembl chr 1:135,190,450...135,211,822

G

ribosomal protein S6 kinase, polypeptide 1

CTD Direct Evidence: marker/mechanism

NCBI chr11:86,389,695...86,435,711
Ensembl chr11:86,389,697...86,435,631

G

S100 protein, beta polypeptide, neural

protein:increased expression:serum

RGD

NCBI chr10:76,089,670...76,097,153
Ensembl chr10:76,089,687...76,096,993

G

sphingosine-1-phosphate receptor 1

disease_progression

associated with SHRSP;mRNA,protein:increased expression, decreased expression:kidney (rat)

RGD

NCBI chr 3:115,504,082...115,508,704
Ensembl chr 3:115,504,082...115,508,721

G

sodium channel, nonvoltage-gated 1 alpha

CTD Direct Evidence: marker/mechanism

PMID:11752024 PMID:23348737

NCBI chr 6:125,286,657...125,321,906
Ensembl chr 6:125,297,622...125,321,906

G

sodium channel, nonvoltage-gated 1 beta

CTD Direct Evidence: marker/mechanism

PMID:15174897 PMID:15198480 PMID:19344079

NCBI chr 7:121,464,261...121,517,951
Ensembl chr 7:121,464,261...121,517,737

G

sodium channel, nonvoltage-gated 1 gamma

CTD Direct Evidence: marker/mechanism

NCBI chr 7:121,333,643...121,367,705
Ensembl chr 7:121,333,702...121,367,698

G

selectin, platelet

CTD Direct Evidence: marker/mechanism

NCBI chr 1:163,942,833...163,977,595
Ensembl chr 1:163,942,833...163,977,595

G

serine (or cysteine) peptidase inhibitor, clade E, member 1

treatment

protein:increased expression:plasma (human)
mRNA:increased expression:kidney (SHRSP/A3N rat)
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:21051829 PMID:22352330 PMID:8355419 PMID:11907153 PMID:16645728

RGD:8547753, RGD:28912746, RGD:11081003

NCBI chr 5:137,090,358...137,101,126
Ensembl chr 5:137,090,358...137,101,122

G

serine (or cysteine) peptidase inhibitor, clade E, member 2

mRNA, protein:increased expression:blood vessel

RGD

NCBI chr 1:79,772,038...79,836,382
Ensembl chr 1:79,771,914...79,838,897

G

serine (or cysteine) peptidase inhibitor, clade F, member 2

RGD

NCBI chr11:75,322,562...75,330,327
Ensembl chr11:75,322,558...75,330,417

G

serum/glucocorticoid regulated kinase 1

no_association
susceptibility

DNA:snps:exon, intron: (human)

RGD

PMID:15304560 PMID:16221215

RGD:1580969, RGD:1580968

NCBI chr10:21,758,083...21,875,802
Ensembl chr10:21,758,083...21,875,802

G

SH2B adaptor protein 3

RGD

NCBI chr 5:121,953,544...121,975,706
Ensembl chr 5:121,953,551...121,975,709

G

sirtuin 6

exacerbates

RGD

NCBI chr10:81,457,621...81,463,631
Ensembl chr10:81,457,619...81,463,631

G

solute carrier family 12, member 2

mRNA:increased expression:aorta
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:17259435 PMID:15020309 PMID:21814290

RGD:1580582, RGD:9587757

NCBI chr18:58,011,505...58,079,893
Ensembl chr18:58,011,750...58,079,893

G

solute carrier family 12, member 3

CTD Direct Evidence: marker/mechanism

NCBI chr 8:95,055,737...95,092,850
Ensembl chr 8:95,055,829...95,092,842

G

solute carrier family 26, member 4

RGD

NCBI chr12:31,569,813...31,610,054
Ensembl chr12:31,569,826...31,609,968

G

solute carrier family 2 (facilitated glucose transporter), member 1

protein:increased expression:renal glomerulus

RGD

NCBI chr 4:118,966,001...118,994,527
Ensembl chr 4:118,965,908...118,995,180

G

solute carrier family 2 (facilitated glucose transporter), member 3

RGD

NCBI chr 6:122,704,783...122,779,149
Ensembl chr 6:122,704,768...122,778,599

G

solute carrier family 4 (anion exchanger), member 4

protein:increased expression:kidney cortex

RGD

NCBI chr 5:88,941,717...89,387,515
Ensembl chr 5:89,034,345...89,387,512

G

solute carrier family 5 (sodium/glucose cotransporter), member 2

RGD

NCBI chr 7:127,864,855...127,871,602
Ensembl chr 7:127,864,829...127,871,602

G

solute carrier family 6 (neurotransmitter transporter), member 18

CTD Direct Evidence: marker/mechanism

NCBI chr13:73,809,869...73,826,142
Ensembl chr13:73,809,871...73,826,142

G

solute carrier family 6 (neurotransmitter transporter), member 19

mRNA:increased expression

NCBI chr13:73,827,864...73,848,899
Ensembl chr13:73,827,864...73,852,984

G

solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2

DNA:polymorphism:1287G>A
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:22533655 PMID:17124432

NCBI chr 8:93,687,100...93,728,295
Ensembl chr 8:93,686,707...93,728,295

G

solute carrier family 6 (neurotransmitter transporter, dopamine), member 3

protein:increased expression:caudate-putamen

RGD

NCBI chr13:73,684,270...73,726,791
Ensembl chr13:73,684,866...73,726,791

G

solute carrier family 8 (sodium/calcium exchanger), member 1

DNA:SNP: :1784C>T
DNA:snps:intron:g.-23200T>C, g.-23181T>C (human)

RGD

PMID:16343576 PMID:15824464 PMID:15785003

RGD:1598724, RGD:1580586, RGD:1580732

NCBI chr17:81,680,534...82,045,816
Ensembl chr17:81,680,534...82,045,806

G

solute carrier family 9 (sodium/hydrogen exchanger), member 3

RGD

NCBI chr13:74,234,374...74,317,561
Ensembl chr13:74,269,576...74,317,561

G

superoxide dismutase 1, soluble

treatment

associated with Hydronephrosis
CTD Direct Evidence: marker/mechanism|therapeutic
human gene in a rat model
mRNA:decreased expression:rostral ventrolateral medulla (rat)

CTD
RGD

PMID:9024144 PMID:25101153 PMID:32165127 PMID:19403858 PMID:31572179 More...

RGD:2312366, RGD:329956417, RGD:1580833, RGD:1581232, RGD:1580833, RGD:1600704

NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217

G

superoxide dismutase 2, mitochondrial

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:11834524 PMID:21593737 PMID:25101153 PMID:16716903

NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950

G

superoxide dismutase 3, extracellular

CTD Direct Evidence: marker/mechanism|therapeutic

CTD
RGD

PMID:16864745 PMID:17023265 PMID:12600899 PMID:16864745

RGD:1580845, RGD:1581232

NCBI chr 5:52,521,146...52,527,080
Ensembl chr 5:52,521,133...52,528,760

G

sequestosome 1

protein:decreased expression:brain

RGD

NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654

G

Rous sarcoma oncogene

RGD

NCBI chr 2:157,265,828...157,313,758
Ensembl chr 2:157,260,364...157,313,782

G

serum response factor

RGD

NCBI chr17:46,857,764...46,869,194
Ensembl chr17:46,859,255...46,867,101

G

somatostatin

protein:altered expression:stomach

RGD

NCBI chr16:23,708,327...23,710,041
Ensembl chr16:23,708,323...23,709,708

G

stromal interaction molecule 1

CTD Direct Evidence: marker/mechanism

NCBI chr 7:101,909,279...102,086,525
Ensembl chr 7:101,917,013...102,086,526

G

serine/threonine kinase 11

CTD Direct Evidence: marker/mechanism

NCBI chr10:79,951,602...79,966,513
Ensembl chr10:79,951,637...79,966,516

G

serine/threonine kinase 39

CTD Direct Evidence: therapeutic

NCBI chr 2:68,040,789...68,302,381
Ensembl chr 2:68,040,789...68,302,612

G

steroid sulfatase

protein:increased expression:multiple organs

RGD

NCBI chr X:168,856,332...169,015,037
Ensembl chr X:168,909,030...169,014,924

G

tachykinin 2

protein:increased expression:supraoptic nucleus, medulla oblongata

RGD

NCBI chr10:127,560,347...127,567,637
Ensembl chr10:127,560,347...127,567,637

G

tachykinin receptor 1

CTD Direct Evidence: marker/mechanism

NCBI chr 6:82,378,990...82,537,085
Ensembl chr 6:82,379,315...82,537,085

G

tachykinin receptor 3

RGD

NCBI chr 3:134,534,768...134,640,342
Ensembl chr 3:134,534,768...134,640,340

G

thromboxane A synthase 1, platelet

associated with hyperinsulinism

RGD

PMID:9370383 PMID:16192456

RGD:1601472, RGD:1601439

NCBI chr 6:38,817,897...39,061,524
Ensembl chr 6:38,852,338...39,061,519

G

transforming growth factor, beta 1

protein:increased expression:vascular associated smooth muscle cell
protein:increased expression:blood serum (human)
mRNA:increased expression:kidney (SHRSP/A3N rat)
protein:increased expression:renal glomerulus
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:11682445 PMID:19018797 PMID:17364610 PMID:26502942 PMID:11907153 More...

RGD:1601552, RGD:329955577, RGD:28912746, RGD:30296650, RGD:12879474, RGD:1331525

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

G

transforming growth factor, beta 3

no_association

DNA:polymorphism, SNPs

RGD

NCBI chr12:86,103,517...86,125,815
Ensembl chr12:86,103,519...86,125,815

G

transglutaminase 2, C polypeptide

CTD Direct Evidence: marker/mechanism

NCBI chr 2:157,958,325...157,988,312
Ensembl chr 2:157,958,322...157,988,356

G

tyrosine hydroxylase

susceptibility

mRNA:increased expression:brain
CTD Direct Evidence: marker/mechanism
DNA:polymorphism:intron:g.1090T>C rs2070762 (human)

CTD
RGD

PMID:27659729 PMID:32147540 PMID:32165127 PMID:16650497 PMID:16636198

RGD:1601630, RGD:1601631

NCBI chr 7:142,446,516...142,453,732
Ensembl chr 7:142,446,489...142,484,865

G

thrombomodulin

treatment

protein:increased expression:plasma
protein:decreased expression:plasma
associated with Experimental Diabetes Mellitus

RGD

PMID:17401180 PMID:12611420 PMID:16095049 PMID:14737039

RGD:1601636, RGD:1601652, RGD:5685017, RGD:1601646

NCBI chr 2:148,246,391...148,250,108
Ensembl chr 2:148,246,386...148,250,108

G

tissue inhibitor of metalloproteinase 1

protein:decreased expression:glomerulus
CTD Direct Evidence: marker/mechanism
mRNA, protein:increased expression:kidney

CTD
RGD

PMID:21051829 PMID:19506087 PMID:17977875

RGD:2312464, RGD:2290351

NCBI chr X:20,736,524...20,740,972
Ensembl chr X:20,736,405...20,740,974

G

tight junction protein 2

protein:decreased expression:brain

RGD

NCBI chr19:24,071,860...24,202,492
Ensembl chr19:24,071,869...24,202,394

G

toll-like receptor 4

CTD Direct Evidence: marker/mechanism

PMID:27292124 PMID:32147540

NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521

G

tumor necrosis factor

ameliorates
treatment

associated with Cardiac Fibrosis
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:18605955 PMID:27292124 PMID:27659729 PMID:27847271 PMID:32147540 More...

RGD:1357163, RGD:401794570, RGD:1580207

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)

severity

protein:increased expression:serum

RGD

NCBI chr15:54,114,014...54,141,700
Ensembl chr15:54,114,015...54,141,880

G

tropomyosin 1, alpha

CTD Direct Evidence: marker/mechanism

NCBI chr 9:66,929,872...66,956,954
Ensembl chr 9:66,929,872...66,956,688

G

transferrin

protein:decreased expression

RGD

NCBI chr 9:103,086,075...103,107,485
Ensembl chr 9:103,081,200...103,107,643

G

thyrotropin releasing hormone

protein:decreased expression:diencephalon
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:6350720 PMID:17227965

NCBI chr 6:92,219,042...92,221,631
Ensembl chr 6:92,219,042...92,221,631

G

thyrotropin releasing hormone receptor

RGD

NCBI chr15:44,059,314...44,099,308
Ensembl chr15:44,059,531...44,099,308

G

transformation related protein 53

CTD Direct Evidence: marker/mechanism

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

G

transient receptor potential cation channel, subfamily C, member 3

CTD Direct Evidence: marker/mechanism

NCBI chr 3:36,674,626...36,744,276
Ensembl chr 3:36,674,631...36,744,316

G

transient receptor potential cation channel, subfamily C, member 5

CTD Direct Evidence: marker/mechanism

NCBI chr X:143,160,323...143,471,176
Ensembl chr X:143,164,667...143,471,176

G

urocortin

associated with Pregnancy Complications;protein:increased expression:plasma
CTD Direct Evidence: therapeutic

CTD
RGD

PMID:20237592 PMID:16915033

NCBI chr 5:31,295,333...31,296,239
Ensembl chr 5:31,295,407...31,296,173

G

urocortin 2

human protein in rat model

RGD

NCBI chr 9:108,815,231...108,816,232
Ensembl chr 9:108,815,078...108,816,232

G

uncoupling protein 1 (mitochondrial, proton carrier)

DNA:polymorphism: :-3826A>G (human)

RGD

NCBI chr 8:84,016,977...84,025,085
Ensembl chr 8:84,016,981...84,025,081

G

uncoupling protein 2 (mitochondrial, proton carrier)

treatment

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:16685210 PMID:15106800 PMID:20404217

RGD:1580794, RGD:7175297

NCBI chr 7:100,142,565...100,148,832
Ensembl chr 7:100,142,544...100,151,227

G

uncoupling protein 3 (mitochondrial, proton carrier)

RGD

NCBI chr 7:100,122,198...100,135,639
Ensembl chr 7:100,122,197...100,135,639

G

UDP-glucose ceramide glucosyltransferase

treatment

RGD

NCBI chr 4:59,189,452...59,222,833
Ensembl chr 4:59,189,257...59,222,833

G

uromodulin

CTD Direct Evidence: marker/mechanism

NCBI chr 7:119,061,931...119,078,485
Ensembl chr 7:119,061,934...119,078,505

G

urotensin 2

protein:increased expression:plasma
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:16160878 PMID:15201550 PMID:15201550

RGD:1580808, RGD:1580808

NCBI chr 4:151,081,554...151,086,267
Ensembl chr 4:151,081,554...151,086,267

G

urotensin 2 receptor

RGD

NCBI chr11:121,051,097...121,052,799
Ensembl chr11:121,051,097...121,052,799

G

vav 3 oncogene

CTD Direct Evidence: marker/mechanism

NCBI chr 3:109,247,757...109,593,010
Ensembl chr 3:109,247,969...109,593,014

G

vascular cell adhesion molecule 1

disease_progression

mRNA:increased expression:multiple organs
associated with SHRSP;mRNA,protein:increased expression:kidney, membrane fraction (rat)
CTD Direct Evidence: marker/mechanism
associated with Diabetes Mellitus, Type1; protein:increased expression:serum:

CTD
RGD

PMID:11834524 PMID:19018797 PMID:19080338 PMID:17938382 PMID:20569722

RGD:2313107, RGD:1643008, RGD:7241235

NCBI chr 3:115,903,669...115,923,337
Ensembl chr 3:115,903,598...115,923,337

G

vitamin D (1,25-dihydroxyvitamin D3) receptor

CTD Direct Evidence: marker/mechanism

NCBI chr15:97,752,308...97,806,177
Ensembl chr15:97,752,306...97,808,511

G

vascular endothelial growth factor A

treatment

associated with Prostatic Neoplasms

RGD

PMID:16164572 PMID:20630084

RGD:1580573, RGD:8552374

NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295

G

von Hippel-Lindau tumor suppressor

RGD

NCBI chr 6:113,600,955...113,608,595
Ensembl chr 6:113,600,920...113,608,594

G

Von Willebrand factor

treatment

CTD Direct Evidence: marker/mechanism
associated with Experimental Diabetes Mellitus

CTD
RGD

PMID:12149661 PMID:12425201 PMID:22352330 PMID:14737039

NCBI chr 6:125,529,911...125,663,642
Ensembl chr 6:125,523,737...125,663,642

G

WNK lysine deficient protein kinase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 6:119,900,930...120,015,659
Ensembl chr 6:119,900,930...120,015,633

G

WNK lysine deficient protein kinase 4

no_association

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:22949526 PMID:12642508

NCBI chr11:101,151,363...101,168,235
Ensembl chr11:101,151,393...101,168,235

G

xanthine dehydrogenase

treatment

DNA:SNPs:exon, intron:47686C>T, 69901A>C, 67873A>C (p.N1109T) (human)

RGD

PMID:23746952 PMID:12826072 PMID:18712049 PMID:18728266

RGD:7247630, RGD:13210518, RGD:7247654, RGD:7247653

NCBI chr17:74,190,890...74,257,191
Ensembl chr17:74,190,890...74,257,191

G

X-ray repair complementing defective repair in Chinese hamster cells 1

susceptibility

DNA:SNP,haplotypes: p.R194W, p.R399Q (rs1799782, rs25487) (human)

RGD

NCBI chr 7:24,246,124...24,272,863
Ensembl chr 7:24,245,714...24,272,865

G

X-ray repair complementing defective repair in Chinese hamster cells 3

susceptibility

DNA:SNP,haplotype:cd: p.T241M (rs861539) (human)

NCBI chr12:111,769,626...111,780,326
Ensembl chr12:111,769,626...111,780,307

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide

treatment

RGD

NCBI chr15:36,770,505...36,803,228
Ensembl chr15:36,771,014...36,797,173

benign hypertensive renal disease

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

mitogen-activated protein kinase kinase kinase 7

protein:increased expression:cortex of kidney (human)

RGD

NCBI chr 4:31,963,659...32,023,470
Ensembl chr 4:31,964,097...32,023,467

Diastolic Hypertension, Resistance to

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

Kv channel-interacting protein 1

ClinVar Annotator: match by term: Hypertension, diastolic, resistance to

PMID:15057310 PMID:16155733 PMID:25741868

NCBI chr11:33,579,339...33,943,854
Ensembl chr11:33,579,339...33,943,152

G

potassium large conductance calcium-activated channel, subfamily M, beta member 1

ClinVar Annotator: match by term: Hypertension, diastolic, resistance to
CTD Direct Evidence: marker/mechanism

OMIM
ClinVar
CTD

PMID:15057310 PMID:16155733 PMID:25741868

NCBI chr11:33,912,955...33,923,641
Ensembl chr11:33,913,013...33,923,641

Dursun Syndrome

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

glucose 6 phosphatase, catalytic, 3

ClinVar Annotator: match by term: Dursun syndrome

PMID:25741868 PMID:28492532

NCBI chr11:102,080,525...102,084,907
Ensembl chr11:102,080,446...102,084,907

eclampsia

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

interleukin 6

treatment

RGD

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

essential hypertension

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acyl-CoA synthetase medium-chain family member 3

no_association

RGD

NCBI chr 7:119,360,106...119,384,119
Ensembl chr 7:119,360,146...119,386,736

G

adducin 1

CTD Direct Evidence: marker/mechanism
ClinVar Annotator: match by term: Hypertension, salt-sensitive essential, susceptibility to

OMIM
CTD
ClinVar

PMID:9149697 PMID:9607177 PMID:10024330 PMID:10523341 PMID:11882573 More...

NCBI chr 5:34,731,008...34,789,652
Ensembl chr 5:34,731,008...34,789,652

G

angiotensinogen

ClinVar Annotator: match by term: Essential hypertension, genetic | ClinVar Annotator: match by term: Hypertension, essential, susceptibility to
CTD Direct Evidence: marker/mechanism

PMID:1394429 PMID:7649545 PMID:7883995 PMID:8348146 PMID:8513325 More...

NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445

G

angiotensin II receptor, type 1a

treatment

ClinVar Annotator: match by term: Essential hypertension | ClinVar Annotator: match by term: Essential hypertension, genetic | ClinVar Annotator: match by term: Hypertension, essential, susceptibility to
CTD Direct Evidence: marker/mechanism

ClinVar
CTD
OMIM
RGD

PMID:8021009 PMID:9084931 PMID:15042429 PMID:16116425 PMID:25741868 More...

NCBI chr13:30,520,339...30,566,850
Ensembl chr13:30,520,424...30,566,850

G

allograft inflammatory factor 1

CTD Direct Evidence: marker/mechanism

NCBI chr17:35,389,967...35,394,977
Ensembl chr17:35,389,967...35,395,044

G

ATPase, Na+/K+ transporting, beta 1 polypeptide

CTD Direct Evidence: marker/mechanism

NCBI chr 1:164,264,668...164,285,924
Ensembl chr 1:164,264,678...164,285,924

G

ATPase, Ca++ transporting, cardiac muscle, slow twitch 2

susceptibility

DNA:polymorphism:exon:p.A724A (c.2171G>A)(human)

RGD

NCBI chr 5:122,591,576...122,640,288
Ensembl chr 5:122,591,576...122,640,288

G

ATP synthase peripheral stalk subunit F6

protein:increased expression:plasma (human)

RGD

NCBI chr16:84,624,754...84,632,495
Ensembl chr16:84,624,754...84,632,513

G

calcyon neuron-specific vesicular protein

CTD Direct Evidence: marker/mechanism

NCBI chr 7:139,649,793...139,662,485
Ensembl chr 7:139,649,793...139,662,461

G

catalase

RGD

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

cell division cycle associated 3

ClinVar Annotator: match by term: Hypertension, essential, susceptibility to

PMID:9425898 PMID:10477144 PMID:10523525 PMID:10770297 PMID:10770309 More...

NCBI chr 6:124,806,533...124,810,664
Ensembl chr 6:124,806,510...124,810,664

G

cytochrome b-245, alpha polypeptide

CTD Direct Evidence: marker/mechanism

NCBI chr 8:123,151,510...123,159,679
Ensembl chr 8:123,151,515...123,159,669

G

cytochrome b-245, beta polypeptide

CTD Direct Evidence: marker/mechanism

NCBI chr X:9,301,493...9,354,005
Ensembl chr X:9,301,491...9,354,010

G

cytochrome P450, family 3, subfamily a, polypeptide 13

susceptibility

ClinVar Annotator: match by term: Hypertension, salt-sensitive essential, susceptibility to
CTD Direct Evidence: marker/mechanism

OMIM
ClinVar
CTD

PMID:11279519 PMID:11740341 PMID:12065767 PMID:12754175 PMID:15492926

NCBI chr 5:137,891,195...137,923,872
Ensembl chr 5:137,891,194...137,919,881

G

endothelin converting enzyme 1

CTD Direct Evidence: marker/mechanism

NCBI chr 4:137,589,548...137,692,540
Ensembl chr 4:137,589,548...137,692,540

G

elastin

OMIM:145500 | OMIM:603918 | OMIM:604329 | OMIM:607329 | OMIM:608742 | OMIM:610261 | OMIM:610262 | OMIM:610948 | OMIM:611014

NCBI chr 5:134,731,449...134,776,300
Ensembl chr 5:134,731,447...134,776,177

G

free fatty acid receptor 2

CTD Direct Evidence: marker/mechanism

NCBI chr 7:30,517,778...30,523,200
Ensembl chr 7:30,517,773...30,523,200

G

free fatty acid receptor 3

CTD Direct Evidence: marker/mechanism

NCBI chr 7:30,553,755...30,555,603
Ensembl chr 7:30,553,755...30,555,603

G

fibroblast growth factor receptor 2

sexual_dimorphism

mRNA, protein:decreased expression:inferior vagus X ganglion, nucleus of solitary tract (rat)

RGD

NCBI chr 7:129,764,181...129,868,538
Ensembl chr 7:129,764,181...132,725,079

G

FTO alpha-ketoglutarate dependent dioxygenase

DNA:SNP: :rs8050136 (human)

RGD

NCBI chr 8:92,039,995...92,395,061
Ensembl chr 8:92,040,153...92,395,067

G

GATA binding protein 5

OMIM:145500 | OMIM:603918 | OMIM:604329 | OMIM:607329 | OMIM:608742 | OMIM:610261 | OMIM:610262 | OMIM:610948 | OMIM:611014

NCBI chr 2:179,966,881...179,977,296
Ensembl chr 2:179,966,926...179,976,492

G

guanine nucleotide binding protein (G protein), beta 3

susceptibility

ClinVar Annotator: match by term: Hypertension, essential, susceptibility to
CTD Direct Evidence: marker/mechanism
DNA:SNP: :rs5443, rs1129649 (human)

ClinVar
OMIM
CTD
RGD

PMID:9425898 PMID:10477144 PMID:10523525 PMID:10770297 PMID:10770309 More...

NCBI chr 6:124,811,203...124,817,238
Ensembl chr 6:124,811,203...124,817,238

G

G protein-coupled receptor kinase 4

susceptibility

DNA:SNP,haplotypes:cds:

PMID:15097232 PMID:15097232

RGD:1598505, RGD:1598505

NCBI chr 5:34,817,641...34,912,649
Ensembl chr 5:34,817,723...34,912,649

G

hepatitis A virus cellular receptor 1

protein:increased expression:urine:

RGD

NCBI chr11:46,630,644...46,670,405
Ensembl chr11:46,625,907...46,670,405

G

hydroxycarboxylic acid receptor 2

CTD Direct Evidence: marker/mechanism

NCBI chr 5:124,001,633...124,003,579
Ensembl chr 5:124,001,633...124,003,562

G

high mobility group box 1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:148,983,512...148,989,867
Ensembl chr 5:148,983,512...149,121,299

G

hydroxysteroid 11-beta dehydrogenase 1

susceptibility

DNA:SNP:insertion: ins4436A (rs45487298) (human)

RGD

NCBI chr 1:192,903,917...192,946,345
Ensembl chr 1:192,903,942...192,946,383

G

interleukin 1 beta

CTD Direct Evidence: marker/mechanism

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

lipocalin 2

protein:increased expression:urine:

RGD

NCBI chr 2:32,274,649...32,277,751
Ensembl chr 2:32,274,645...32,278,264

G

microRNA 126a

RNA:decreased expression:peripheral blood mononuclear cell

RGD

NCBI chr 2:26,481,369...26,481,441
Ensembl chr 2:26,481,369...26,481,441

G

neutrophil cytosolic factor 1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:134,248,907...134,258,479
Ensembl chr 5:134,248,907...134,258,479

G

nitric oxide synthase 3, endothelial cell

DNA:snp:cds:p.E298D (human)
CTD Direct Evidence: marker/mechanism
ClinVar Annotator: match by term: Essential hypertension
OMIM:145500 | OMIM:603918 | OMIM:604329 | OMIM:607329 | OMIM:608742 | OMIM:610261 | OMIM:610262 | OMIM:610948 | OMIM:611014
DNA:repeats:intron:IVS13+?-?dupCA (human)

CTD
ClinVar
MouseDO
RGD

PMID:25741868 PMID:11394896 PMID:9084930

RGD:1580280, RGD:1580277

NCBI chr 5:24,569,772...24,589,472
Ensembl chr 5:24,569,808...24,589,472

G

natriuretic peptide type B

protein:increased expression:plasma:

RGD

NCBI chr 4:148,070,264...148,071,662
Ensembl chr 4:148,070,245...148,071,662

G

natriuretic peptide receptor 2

DNA:repeat:intron:IVS2+150(GT)10-11 (human)

RGD

NCBI chr 4:43,629,015...43,651,437
Ensembl chr 4:43,631,935...43,651,244

G

occludin

CTD Direct Evidence: marker/mechanism

NCBI chr13:100,633,012...100,689,226
Ensembl chr13:100,633,015...100,689,226

G

phosphatase and actin regulator 1

susceptibility

DNA:SNP::g.12903725A>G (rs9349379) (human)

RGD

NCBI chr13:42,833,909...43,292,002
Ensembl chr13:42,834,099...43,292,002

G

prostaglandin I2 (prostacyclin) synthase

CTD Direct Evidence: marker/mechanism
ClinVar Annotator: match by term: Essential hypertension | ClinVar Annotator: match by term: Essential hypertension, genetic

OMIM
CTD
ClinVar

PMID:12372404 PMID:25741868

NCBI chr 2:167,045,114...167,095,069
Ensembl chr 2:167,033,725...167,082,524

G

protein tyrosine phosphatase, non-receptor type 1

susceptibility

DNA:SNPs::g.54281T>A, 15/37C>A (human)

RGD

NCBI chr 2:167,772,670...167,821,305
Ensembl chr 2:167,773,977...167,821,305

G

retinoic acid receptor responder (tazarotene induced) 2

protein:increased expression:serum:

RGD

NCBI chr 6:48,546,630...48,549,778
Ensembl chr 6:48,546,630...48,549,723

G

retinol binding protein 4, plasma

disease_progression

protein:increased expression:blood plasma (human)
protein:increased expression:blood serum (human)

RGD

PMID:31865725 PMID:19556974

RGD:329845583, RGD:329845861

NCBI chr19:38,105,068...38,113,769
Ensembl chr19:38,105,077...38,113,729

G

renin 1 structural

RGD

NCBI chr 1:133,278,412...133,288,058
Ensembl chr 1:133,278,248...133,288,063

G

regulator of G-protein signaling 5

CTD Direct Evidence: marker/mechanism

NCBI chr 1:169,483,070...169,523,367
Ensembl chr 1:169,483,070...169,523,382

G

renalase, FAD-dependent amine oxidase

DNA:SNPs: :rs2576178, rs2296545,rs2114406 (human)

RGD

NCBI chr19:33,115,140...33,369,695
Ensembl chr19:33,115,147...33,369,665

G

solute carrier family 12, member 3

severity

DNA:missense mutation:cds:p.R904Q (human)
DNA:snp:intron:g.1784C>T (human)

RGD

PMID:15480096 PMID:15824464

RGD:1580589, RGD:1580586

NCBI chr 8:95,055,737...95,092,850
Ensembl chr 8:95,055,829...95,092,842

G

tyrosine hydroxylase

CTD Direct Evidence: marker/mechanism

NCBI chr 7:142,446,516...142,453,732
Ensembl chr 7:142,446,489...142,484,865

G

tight junction protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr 7:64,945,913...65,177,629
Ensembl chr 7:64,945,913...65,177,529

G

toll-like receptor 2

CTD Direct Evidence: marker/mechanism

NCBI chr 3:83,743,579...83,749,045
Ensembl chr 3:83,743,579...83,749,074

G

toll-like receptor 4

CTD Direct Evidence: marker/mechanism

NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521

G

tumor necrosis factor

CTD Direct Evidence: marker/mechanism

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

uromodulin

ClinVar Annotator: match by term: Essential hypertension

NCBI chr 7:119,061,931...119,078,485
Ensembl chr 7:119,061,934...119,078,505

G

zinc finger and SCAN domain containing 25

ClinVar Annotator: match by term: Hypertension, salt-sensitive essential, susceptibility to

PMID:11279519 PMID:11740341 PMID:12065767 PMID:12754175 PMID:15492926

NCBI chr 5:145,217,261...145,229,050
Ensembl chr 5:145,217,310...145,228,088

Grange Syndrome

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

death associated protein 3

ClinVar Annotator: match by term: Grange syndrome

NCBI chr 3:88,828,110...88,858,504
Ensembl chr 3:88,828,110...88,858,488

HELLP syndrome

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ADAM metallopeptidase with thrombospondin type 1 motif 13

protein:decreased activity:plasma (human)

RGD

NCBI chr 2:26,863,363...26,899,638
Ensembl chr 2:26,863,428...26,899,640

G

alpha hemoglobin stabilizing protein

mRNA:decreased expression:placenta (human)

RGD

NCBI chr 7:127,902,016...127,902,926
Ensembl chr 7:127,901,969...127,902,930

G

CD40 ligand

protein:increased expression:blood platelet (human)

RGD

NCBI chr X:56,257,448...56,269,402
Ensembl chr X:56,257,503...56,269,402

G

erb-b2 receptor tyrosine kinase 2

RGD

NCBI chr11:98,303,310...98,328,542
Ensembl chr11:98,303,296...98,328,542

G

Fas cell surface death receptor

susceptibility

DNA:SNP:promoter:-670A>G(rs1800682)(human)
protein,mRNA:altered expression:placenta, liver:

RGD

PMID:30066360 PMID:28501275

RGD:14700669, RGD:14700673

NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172

G

Fas ligand

susceptibility

DNA:SNP:intron:124A>G(rs5030772)(human)
protein:altered expression:blood, placenta, liver:

RGD

PMID:30066360 PMID:28501275

RGD:14700669, RGD:14700673

NCBI chr 1:161,608,260...161,616,064
Ensembl chr 1:161,608,258...161,616,064

HUPRA Syndrome

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

seryl-tRNA synthetase 1

ClinVar Annotator: match by term: HYPERURICEMIA, PULMONARY HYPERTENSION, RENAL FAILURE, AND ALKALOSIS SYNDROME

PMID:25741868 PMID:28492532

NCBI chr 3:108,332,180...108,352,575
Ensembl chr 3:108,332,181...108,352,525

G

seryl-aminoacyl-tRNA synthetase 2

ClinVar Annotator: match by term: HYPERURICEMIA, PULMONARY HYPERTENSION, RENAL FAILURE, AND ALKALOSIS SYNDROME | ClinVar Annotator: match by term: Hyperuricemia, pulmonary hypertension, renal failure, and alkalosis
DNA:missense mutation:CDS:p.D390G (human)

OMIM
ClinVar
RGD

PMID:9536098 PMID:17576681 PMID:21255763 PMID:24034276 PMID:25741868 More...

NCBI chr 7:28,441,393...28,453,304
Ensembl chr 7:28,441,417...28,453,296

hypertension and brachydactyly syndrome

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

phosphodiesterase 3A, cGMP inhibited

ClinVar Annotator: match by term: Bilginturan syndrome
CTD Direct Evidence: marker/mechanism

OMIM
ClinVar
CTD

PMID:4774535 PMID:25741868 PMID:25961942 PMID:28492532 PMID:29758562 More...

NCBI chr 6:141,194,995...141,452,588
Ensembl chr 6:141,194,995...141,453,174

Hypertension Resistant to Conventional Therapy

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

glutathione S-transferase, mu 1

susceptibility

DNA:deletion:cds: (human)

RGD

NCBI chr 3:107,919,566...107,925,289
Ensembl chr 3:107,919,571...107,925,289

G

nitric oxide synthase 3, endothelial cell

ClinVar Annotator: match by term: Hypertension resistant to conventional therapy

PMID:9737779 PMID:9894802 PMID:10475066 PMID:10510054 PMID:10514107 More...

NCBI chr 5:24,569,772...24,589,472
Ensembl chr 5:24,569,808...24,589,472

G

protein tyrosine phosphatase receptor type D

susceptibility

associated with coronary artery disease;DNA:SNP:intron: (rs324498) (human)

RGD

NCBI chr 4:75,859,474...78,132,282
Ensembl chr 4:75,859,475...78,130,198

Hypertension, Early-Onset, Autosomal Dominant, with Severe Exacerbation in Pregnancy

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

nuclear receptor subfamily 3, group C, member 2

CTD Direct Evidence: marker/mechanism
ClinVar Annotator: match by term: Hypertension, early-onset, autosomal dominant, with exacerbation in pregnancy | ClinVar Annotator: match by term: Hypertension, early-onset, autosomal dominant, with severe exacerbation in pregnancy

OMIM
CTD
ClinVar

PMID:10884226 PMID:15126534 PMID:16757525 PMID:22463955 PMID:25741868 More...

NCBI chr 8:77,626,422...77,971,641
Ensembl chr 8:77,626,070...77,971,641

Hypertensive Nephropathy

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensinogen

treatment

RGD

NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445

G

angiotensin II receptor, type 1a

treatment

RGD

NCBI chr13:30,520,339...30,566,850
Ensembl chr13:30,520,424...30,566,850

G

cofilin 1, non-muscle

protein:increased phosphorylation:kidney (rat)

RGD

NCBI chr19:5,540,483...5,544,059
Ensembl chr19:5,540,483...5,545,229

G

collagen, type I, alpha 1

mRNA:increased expression:juxtamedullary cortex (rat)

RGD

NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868

G

haptoglobin

treatment

RGD

NCBI chr 8:110,301,760...110,305,804
Ensembl chr 8:110,301,760...110,305,804

G

matrix metallopeptidase 2

ameliorates

RGD

NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048

G

natriuretic peptide type B

RGD

NCBI chr 4:148,070,264...148,071,662
Ensembl chr 4:148,070,245...148,071,662

G

periostin, osteoblast specific factor

disease_progression

mRNA,protein:increased expression:kidney:

RGD

NCBI chr 3:54,266,688...54,298,462
Ensembl chr 3:54,268,530...54,298,458

G

peroxisome proliferator activated receptor alpha

RGD

NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020

G

recombination activating 1

ameliorates

RGD

PMID:23364523 PMID:23364523

RGD:7207429, RGD:7207429

NCBI chr 2:101,468,597...101,479,877
Ensembl chr 2:101,468,627...101,479,846

G

src homology 2 domain-containing transforming protein C1

protein:increased expression:kidney

RGD

NCBI chr 3:89,325,858...89,337,336
Ensembl chr 3:89,325,750...89,337,334

G

sirtuin 6

protein:decreased expression:kidney

RGD

NCBI chr10:81,457,621...81,463,631
Ensembl chr10:81,457,619...81,463,631

Hypertensive Nephrosclerosis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

treatment
severity

protein:increased expression:nephron tubule, kidney interstitium (human)

RGD

PMID:10580398 PMID:21346373

RGD:12879397, RGD:40818408

NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790

G

angiotensin converting enzyme 2

severity

mRNA, protein:decreased expression, increased expression:nephron tubule, kidney interstitium (human)

RGD

NCBI chr X:162,922,338...162,971,414
Ensembl chr X:162,922,328...162,971,416

G

microRNA 214

RNA:increased expression:kidney

RGD

NCBI chr 1:162,050,937...162,051,046
Ensembl chr 1:162,050,937...162,051,046

hypertensive retinopathy

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

C-reactive protein, pentraxin-related

protein:increased expression:blood:

RGD

NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598

G

SRY (sex determining region Y)-box 17

treatment

RGD

NCBI chr 1:4,561,154...4,567,624
Ensembl chr 1:4,561,154...4,567,577

Hypomagnesemia, Hypertension, and Hypercholesterolemia, Mitochondrial

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

tRNA isoleucine, mitochondrial

ClinVar Annotator: match by term: Hypomagnesemia, hypertension, and hypercholesterolemia, mitochondrial

PMID:15498972 PMID:34607911

NCBI chr MT:3,706...3,774
Ensembl chr MT:3,706...3,774

Isolated Systolic Hypertension

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

apolipoprotein B

ClinVar Annotator: match by term: Isolated systolic hypertension

PMID:25741868 PMID:28492532

NCBI chr12:8,027,629...8,066,839
Ensembl chr12:8,027,648...8,066,835

G

BSCL2 lipid droplet biogenesis associated, seipin

ClinVar Annotator: match by term: Isolated systolic hypertension

PMID:25741868 PMID:28492532

NCBI chr19:8,814,831...8,826,047
Ensembl chr19:8,814,831...8,826,047
Ensembl chr 2:8,814,831...8,826,047

malignant hypertension

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenomedullin

protein:increased expression:plasma

RGD

NCBI chr 7:110,226,864...110,229,027
Ensembl chr 7:110,226,868...110,229,027

G

angiotensinogen

CTD Direct Evidence: marker/mechanism

PMID:2493837 PMID:27428043

NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445

G

cytochrome P450, family 17, subfamily a, polypeptide 1

CTD Direct Evidence: marker/mechanism

NCBI chr19:46,655,604...46,661,439
Ensembl chr19:46,655,604...46,661,611

G

renin 1 structural

CTD Direct Evidence: marker/mechanism

NCBI chr 1:133,278,412...133,288,058
Ensembl chr 1:133,278,248...133,288,063

G

renin 2 tandem duplication of Ren1

CTD Direct Evidence: marker/mechanism

Masked Hypertension

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adiponectin, C1Q and collagen domain containing

protein:decreased expression:plasma

RGD

NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778

mild pre-eclampsia

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

glutathione peroxidase 3

protein:increased expression:plasma

RGD

NCBI chr11:54,793,680...54,801,213
Ensembl chr11:54,793,279...54,801,203

Neonatal Pulmonary Hypertension

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

carbamoyl-phosphate synthetase 1

ClinVar Annotator: match by term: Pulmonary hypertension, neonatal, susceptibility to

PMID:8486760 PMID:9536098 PMID:9686343 PMID:9711878 PMID:11388595 More...

NCBI chr 1:67,151,294...67,270,426
Ensembl chr 1:67,162,185...67,270,418

nephrosclerosis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

actin alpha 2, smooth muscle, aorta

CTD Direct Evidence: marker/mechanism

NCBI chr19:34,217,736...34,232,985
Ensembl chr19:34,218,490...34,232,990

G

adrenergic receptor, beta 1

disease_progression

associated with hypertension;DNA:missense mutations, haplotype:cds:p.S49G(rs1801252),p.R389G (rs1801253)(human):

RGD

NCBI chr19:56,710,549...56,713,582
Ensembl chr19:56,710,631...56,721,545

G

arachidonate 5-lipoxygenase

CTD Direct Evidence: marker/mechanism

NCBI chr 6:116,387,030...116,438,139
Ensembl chr 6:116,387,038...116,438,139

G

alpha-kinase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 3:127,460,367...127,574,195
Ensembl chr 3:127,463,959...127,574,176

G

collagen, type I, alpha 1

CTD Direct Evidence: marker/mechanism

NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868

G

collagen, type III, alpha 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:45,350,698...45,388,866
Ensembl chr 1:45,350,698...45,388,866

G

C-X-C motif chemokine ligand 12

CTD Direct Evidence: marker/mechanism

NCBI chr 6:117,145,496...117,158,329
Ensembl chr 6:117,145,496...117,158,328

G

C-X-C motif chemokine receptor 4

CTD Direct Evidence: marker/mechanism

NCBI chr 1:128,515,936...128,520,036
Ensembl chr 1:128,515,936...128,520,030

G